

**GEORGE KELLY SIBERRY, MD, MPH**  
*Curriculum Vitae*

---

George Kelly Siberry, MD, MPH

---

March 21, 2023

**DEMOGRAPHIC INFORMATION**

**Current Appointments:** Medical Officer, Adult Care & Treatment Branch, Prevention Care and Treatment Division, Office of HIV/AIDS, Global Health Bureau, United States Agency for International Development (USAID). (Aug 2018-present)

Clinical Professor, Adjunct Faculty, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (Jul 2021-present)

**Personal Contact Data:** United States Agency for International Development (USAID)  
500 D Street SW, Washington, DC 20547  
Phone: 202-808-5849  
E-mail: [gsiberry@usaid.gov](mailto:gsiberry@usaid.gov)

**Education and Training:**

1984 – 1988 Sc.B., Neuroscience, Brown University, Providence, Rhode Island, *Magna cum laude*.

1989 – 1994 M.D./M.P.H. Johns Hopkins University School of Medicine and School of Hygiene & Public Health, Baltimore, Maryland.

1994 – 1997 Residency in Pediatrics, Johns Hopkins University School of Medicine, Department of Pediatrics, Baltimore, Maryland. Initial Board Certification: 1997.

1998 – 1999 Chief Resident in Pediatrics, Johns Hopkins University School of Medicine, Department of Pediatrics, Baltimore, Maryland 1998-1999. Co-editor of the *Harriet Lane Handbook*, fifteenth edition.

2000 - 2003 Fellowship in Pediatric Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland. Initial Board Certification: 2003.

**Professional Experience & Employment:**

1988-1989 Country Director, The Haitian Project, Port-au-Prince, Haiti.  
-Louverture-Cleary Secondary School: supervised school construction, hired and managed faculty and support staff, developed a curriculum and system to select meritorious students for this tuition-free boarding school in its founding year.

-Foyer St. Michel (orphanage): responsible for 40 homeless boys and staff.  
<http://haitianproject.org/>

- 1990 Project Coordinator, Long-term follow-up study of HIV transmission, Port-au-Prince, Haiti. Preceptor: Neal Halsey, MD, Johns Hopkins School of Hygiene & Public Health, Baltimore, Maryland.
- 1991, 1993 Project Coordinator, Long-term follow-up studies of early high-titer vs. standard measles vaccines, Haiti. Preceptor: Neal Halsey, MD, Johns Hopkins School of Hygiene & Public Health, Baltimore, Maryland.
- 1997 - 1998 Director, Children's Health Center, Thomas Jefferson University, Philadelphia, Pennsylvania. Supervised physicians & staff of primary care pediatrics clinic for DuPont/Jefferson Pediatric residency training program. Division Director: Gary Emmett, MD.
- 1997 - 2000 Instructor, Department of Pediatrics, Thomas Jefferson University, Philadelphia, Pennsylvania.
- 1999 - 2000 Inpatient Pediatrician, Bryn Mawr Hospital, Bryn Mawr, Pennsylvania. Pediatric Chief: Eric Sundel, MD.
- 2003 - 2008 Director, Harriet Lane Clinic, Department of Pediatrics, Johns Hopkins Medical Institutions, Baltimore, Maryland. Division Chief: Tina Cheng, MD.
- 2001 - 2008 Co-Chair, Infection Control, Kennedy Krieger Institute, Baltimore, Maryland.
- 2003 - 2022 Assistant Professor, Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland. (Full-time 2003-2008; Part-time Aug 2008-Jul 2022)
- 2008 - 2018 Medical Officer (*designation changed to Physician in 2018*), Maternal and Pediatric Infectious Disease (MPID) Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. GS-15 (2015). COR (Contracting Officer Representative) certified: Level II, March 2011; Level III, May 2013.
- 2015 - 2018 Secondment (detail) from NIH to State Department: Senior Pediatric Technical Advisor for PEPFAR, Office of the Global AIDS Coordinator (S/GAC), Department of State, Washington, DC (Nov 2015-Aug 2018). Promoted to Director (supervisory), HIV Treatment, Care & TB Unit (Sept. 2016-Aug 2018). S/GAC Chair for Kenya and Lesotho PEPFAR country programs (from Sept. 2016- Aug 2018).
- 2018- present Medical Officer, Adult Clinical Branch, Division of Prevention, Care and Treatment, Office of HIV/AIDS (OHA), and Deputy Principal (2019-present) for OHA, Global Health Bureau, United States Agency for International Development (USAID), Washington, DC.

- 2019 - 2021 Associate Clinical Professor, Adjunct Faculty, Department of Pediatrics, Yale University School of Medicine, New Haven, CT
- 2021–present Clinical Professor, Adjunct Faculty, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (Jul 2021)
- 2023-present Acting Deputy Office Director, Office of HIV/AIDS, USAID, Washington, DC

## RESEARCH ACTIVITIES

### Publications:

#### Peer-reviewed Scientific Articles

1. Holt EA, Moulton LH, **Siberry** GK and Halsey NA. Differential mortality by measles vaccine titer and sex. *J Infect Dis* 1993;168(5):1087-1096.
2. Utset TO, Golden M, **Siberry** GK, Kiri N, Crum RM, and Petri M. Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system and Sjogren’s syndrome. *J Rheumatol* 1994;21(11):2039-2045.
3. Livingston RA, **Siberry** GK, Paidas CN and Eiden JJ. Appendicitis due to *Mycobacterium avium* complex in an adolescent infected with the human immunodeficiency virus. *Clin Infect Dis* 1995;20(6):1579-1580.
4. **Siberry** GK, Costarangos C and Cohen BA. Destruction of the nasal septum by *Aspergillus* infection after autologous bone marrow transplantation. *New Engl J Med* 1997;337(4):275-6.
5. **Siberry** G, Brahmadathan KN, Pandian R, Lalitha MK, Steinhoff MC, and Jacob John T. Comparison of different culture media and storage temperatures for the long-term preservation of *Streptococcus pneumoniae* in the tropics. *Bull World Health Organ* 2001;79(1):43-47.
6. **Siberry** GK, Diener-West M, Schappell E and Karron RA. Comparison of temple temperatures with rectal temperatures in children under two years of age. *Clin Pediatr* 2002; 41(6):405-414.
7. **Siberry** GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus (MRSA) expressing inducible clindamycin resistance in vitro. *Clin Infect Dis* 2003;37(9):1257-60.
8. Persaud D, **Siberry** GK, Ahonkhai A, Kajdas J, Monie D, Hutton N, Watson DC, Quinn TC, Ray SC, Siliciano RF. Continued production of drug-sensitive HIV-1 in children

- with undetectable viral loads on combination antiretroviral therapy. *J Virol* 2004;78(2):968-79.
9. Jain SJ, Gupta A, Glanz B, Dick J, **Siberry GK**. Antimicrobial-resistant *Shigella sonnei*: Limited antimicrobial treatment options for children and challenges of interpreting *in vitro* azithromycin susceptibility. *Pediatr Infect Dis J*. 2005;24(6):494-7. [Mentored fellow first author, Jain]
  10. Rutstein RM, Gebo KA, **Siberry GK**, Flynn PM, Spector SA, Sharp VL, Fleishman JA. Hospital and Outpatient Health Services Utilization Among HIV-Infected Children in Care 2000-2001. *Med Care*. 2005;43(9 suppl):31-39.
  11. Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, **Siberry GK**, Spector SA. Immunologic Function and Virologic Suppression Among Children With Perinatally Acquired HIV Infection on Highly Active Antiretroviral Therapy. *Med Care*. 2005;43(9 suppl):15-22.
  12. **Siberry GK**, Paquette NR, Ross TL, Perl TM, Valsamakis A. Low prevalence of pertussis among children admitted with respiratory symptoms during Respiratory Syncytial Virus season. *Infect Control Hosp Epidemiol*. 2006;27(1):95-7.
  13. Parsons GN, **Siberry GK**, Parsons JK, Christensen JR, Joyner ML, Lee SL, Kiefner CM, Hutton N. Multidisciplinary, inpatient directly observed therapy for HIV-1 infected children and adolescents failing HAART: a retrospective study. *AIDS Patient Care STDS*. 2006;20(4):275-84.
  14. George-Agwu A, Pasternak R, Joyner M, Carver C, Francis H, **Siberry GK**. Nontypeable Haemophilus Influenzae Meningitis Complicated by Hearing Loss in a 9-year-old HIV-infected Boy. *AIDS Patient Care STDs* 2006;20(8):531-5.
  15. **Siberry GK**, Tessema S. Immune Reconstitution Syndrome Precipitated by Bacille Calmette-Guerin After Initiation of Antiretroviral Therapy. *Pediatr Infect Dis J*. 2006;25(7):648-9.
  16. Chen AE, Goldstein M, Carroll K, Song X, Perl TM, **Siberry GK**. Evolving Epidemiology of Pediatric *Staphylococcus aureus* Cutaneous Infections in a Baltimore Hospital. *Pediatr Emerg Care*. 2006;22(10):717-723. [Mentored fellow first author, Chen]
  17. Arrington-Sanders R, Hutton N, **Siberry GK**. Ritonavir-Fluticasone Interaction Causing Cushing Syndrome in HIV-Infected Children and Adolescents. *Pediatr Infect Dis J* 2006;25(11):1044-48. [Mentored fellow first author, Arrington-Sanders]
  18. Gillenwater KA, Sapp SC, Pearce K, **Siberry GK**. Increase in Tuberculin Skin Test Converters among Healthcare Workers after a Change from Tubersol to Aplisol, *Am J*

- Infect Control* 2006;34(10):651-4.. [Mentored pediatric resident first author, Gillenwater]
19. Milstone AM, Dick J, Carson B, **Siberry GK**. Cerebrospinal Fluid Penetration and Bacteriostatic Activity of Linezolid against *Enterococcus faecalis* in a Child with a Ventriculoperitoneal Shunt Infection. *Pediatric Neurosurgery* 2007;43:406-409.
  20. Persaud D, Ray SC, Kajdas J, Ahonkhai A, **Siberry GK**, Ferguson K, Ziemniak C, Quinn TC, Casazza JP, Zeichner S, Gange SJ, Watson DC. Slow Human Immunodeficiency Virus Type 1 Evolution in Viral Reservoirs in Infants Treated with Effective Antiretroviral Therapy. *AIDS Res Hum Retroviruses* 2007;23(3):381-90.
  21. Szczesiul JM, Shermock KM, Murtaza UI, **Siberry GK**. No Decrease in Clindamycin Susceptibility Despite Increased Use of Clindamycin for Pediatric CA-MRSA Skin Infections. *Pediatr Infect Dis J* 2007; 26(9):852-4.. [Mentored pharmacy resident first author, Szczesiul]
  22. **Siberry GK**, McMillan JA. Corticosteroids for bacterial meningitis [letter]. *N Engl J Med* 2008; 358(13):1400.
  23. **Siberry GK**, Coller RJ, Henkle E, Kiefner C, Joyner M, Rogers J, Chang J, Hutton N. Antibody Response to Hepatitis A Immunization Among Human Immunodeficiency Virus-Infected Children and Adolescents *Pediatr Infect Dis J* 2008; 27(5): 465-8. [Mentored medical student Coller]
  24. Zimmer KP, Solomon BS, **Siberry GK**, Serwint JR. Continuity Structured Clinical Observations (CSCO): Assessing the Multiple Observer Evaluation in a Pediatric Resident Continuity Clinic. *Pediatrics* 2008;121(6):e1633-45.
  25. Chen AE, Cantey JB, Carroll KC, Ross T, Speser S, **Siberry GK**. Discordance Between *S. aureus* Nasal Colonization Skin Infections in Children in the Era of Community-Associated MRSA. *Pediatr Infect Dis J* 2009;28(3):244-6. [Mentored first author, Chen]
  26. **Siberry GK**, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-Philippe P, Kabat W, Nachman S for the IMPAACT P1065 Protocol Team. Phase I/II, Open-Label Trial of Safety and Immunogenicity of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in HIV-Infected Adolescents. *Pediatr Infect Dis J* 2010;29: 391–396.
  27. Brady TM, Solomon BS, Neu AM, **Siberry GK**, Parekh RS. Patient-, Provider-, and Clinic-Level Predictors of Unrecognized Elevated Blood Pressure in Children. *Pediatrics* 2010;125:e1286–e1293.
  28. Oliveira R, Krauss M, Essama-Bibi S, Hofer C, Harris DR, Tiraboschi A, de Souza R, Marques H, Succi R, Abreu T, Della Negra M, Hazra R, Mofenson LM, **Siberry GK**, for the NISDI Pediatric Study Group 2010. Viral load predicts new WHO Stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy,

- independent of CD4 T-lymphocyte value. *Clinical Infectious Diseases* 2010; 51(11):1325-1333. [senior author]
29. Chen AE, Carroll KC, Diener-West M, Ross T, Ordun J, Goldstein MA, Kulkarni G, Cantey JB, **Siberry GK**. Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections. *Pediatrics* 2011;127(3):e573-80.[Mentored first author, Chen]
  30. Steenhoff AP, Josephs J, Rutstein RM, Gebo KA, **Siberry GK**, Gaur AH, Warford R, Korthuis PT, Spector SA, Shah SS. Incidence of and Risk Factors for Community Acquired Pneumonia in US HIV-Infected Children, 2000-2005. *AIDS* 2011;25(5):717-720.
  31. Malee KM, Tassiopoulos K, Huo Y, **Siberry G**, Williams PL, Hazra R, Smith RA, Allison SM, Garvie PA, Kammerer B, Kapetanovic S, Nichols S, Van Dyke R, Seage GR, Mellins CA for the Pediatric HIV/AIDS Cohort Study Team. Mental Health Functioning among Children and Adolescents with Perinatal HIV Infection and Perinatal HIV Exposure. *AIDS Care* 2011;23(12):1533-44.
  32. Tamhane M, Gautney B, Shiu C, Segaren N, Jeannis L, Eustache C, Simeon-Fadois Y, Chen YH, De D, Irvinti S, Tamma P, Thompson CB, Khamadi S, **Siberry GK**, Persaud D. Analysis of the optimal cut-point for HIV-p24 antigen testing to diagnose HIV infection in HIV-exposed children from resource-constrained settings. *J Clin Virol* 2011;50(4): 338-41.
  33. Van Dyke RB, Patel K, **Siberry GK**, Burchett SK, Spector SA, Chernoff MC, Read JS, Mofenson LM, Seage GR 3rd; for the Pediatric HIV/AIDS Cohort Study. Antiretroviral Treatment of U.S. Children with Perinatally Acquired HIV Infection: Temporal Changes in Therapy between 1991 and 2009 and Predictors of Immunologic and Virologic Outcomes. *J Acquir Immune Defic Syndr* 2011; 57(2):165-73.
  34. **Siberry GK**, Patel K, Van Dyke RB, Hazra R, Burchett SK, Spector SA, Paul ME, Read JS, Wiznia A, Seage GR 3rd; for the Pediatric HIV/AIDS Cohort Study (PHACS). CD4+ Lymphocyte-Based Immunologic Outcomes of Perinatally HIV-Infected Children During Antiretroviral Therapy Interruption. *J Acquir Immune Defic Syndr* 2011; 57(3):223-229.
  35. Agwu AL, Fleishman JA, Korthuis PT, **Siberry GK**, Ellen JM, Gaur AH, Rutstein R, and Gebo KA for the HIV Research Network. Disparities in Antiretroviral Treatment: A Comparison of Behaviorally-HIV-Infected Youth and Adults in the HIV Research Network. *J Acquir Immune Defic Syndr* 2011;58(1):100-107.
  36. Setse RW, **Siberry GK**, Gravitt PE, Moss WJ, Agwu A, Wheeling T, Bohannon B, Dominguez K and LEGACY Consortium. Correlates of Sexual Activity and Sexually

Transmitted Infections among Perinatally HIV-Infected Youth in the LEGACY Cohort, United States, 2006. *Pediatr Infect Dis J* 2011; 30(11):967-973.

37. Jacobson DL, Patel K, **Siberry GK**, Van Dyke RB, DiMeglio LA, Geffner ME, Chen JS, McFarland EJ, Borkowsky W, Silio M, Fielding RA, Siminski S, Miller TL, for the Pediatric HIV/AIDS Cohort Study. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: Outcomes from the Pediatric HIV/AIDS Cohort Study (PHACS). *American Journal of Clinical Nutrition* 2011; 94(6):1485-1495.
38. **Siberry GK**, Li H, Jacobson D. Fracture Risk by HIV Infection Status in Perinatally HIV-Exposed Children. *AIDS Res Hum Retroviruses* 2012;28(3):247-50.
39. Agwu AL, **Siberry GK**, Ellen JM, Fleishman JA, Rutstein R, Gaur AH, Korthuis PT, Warford R, Spector SA, and Gebo KA. Predictors of HAART Utilization for Behaviorally HIV-1 Infected Youth: Impact of Adult vs. Pediatric Clinical Care Site. *J Adolesc Health* 2012; 50(5):471-7.
40. Setse RW, **Siberry GK**, Moss WJ, Gravitt PE, Wheeling JT, Bohannon B, Dominguez K, and the Legacy Consortium. Cervical Pap Screening Cytological Abnormalities among HIV-Infected Adolescents in the LEGACY Cohort. *Journal of Pediatric and Adolescent Gynecology* 2012; 25(1):27-34.
41. Williams PL, Van Dyke RB, **Siberry GK**, Griner R, Seage GR, Tassiopoulos K, Yildirim C, Read JS, Huo Y, Hazra R, Jacobson DL, Mofenson LM, and Rich K for the Pediatric HIV/AIDS Cohort Study. A Trigger-Based Design for Evaluating the Safety of in utero Antiretroviral Exposure in Uninfected Children of HIV-Infected Mothers. *American Journal of Epidemiology* 2012;175(9):950-61.
42. Miller TL, Borkowsky W, DiMeglio LA, Dooley L, Geffner ME, Hazra R, McFarland EJ, Mendez AJ, Patel K, **Siberry GK**, Van Dyke RB, Worrell CJ, Jacobson DL for the Pediatric HIV/AIDS Cohort Study (PHACS). Metabolic Abnormalities and Viral Replication Associated with Biomarkers of Vascular Dysfunction in HIV-Infected Children. *HIV Medicine* 2012;13(5):264-275.
43. **Siberry GK**, Warshaw MG, Williams PL, Spector SA, Decker MD, Jean-Philippe P, Yogev R, Heckman BE, Manzella A, Roa J, Nachman S, Lujan-Zilbermann J; for the IMPAACT P1065 Protocol Team. Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in 2- to 10-year-old Human Immunodeficiency Virus-infected Children. *Pediatr Infect Dis J*. 2012;31(1):47-52.
44. **Siberry GK**, Leister E, Jacobson D, Foster SB, Seage GR, Lipshultz SE, Paul ME, Purswani M, Colin AA, Scott G, and Shearer WT, for the Pediatric HIV/AIDS Cohort Study (PHACS) Group. Increased risk of asthma and atopic dermatitis in perinatally HIV-infected children and adolescents. *Clin Immunol*. 2012;142(2):201-8.

45. Miller EK, Hernandez JZ, Wimmenauer V, Shepherd BE, Hijano D, Libster R, Serra ME, Bhat N, Batalle JP, Mohamed Y, Reynaldi A, Rodriguez A, Otello M, Pisapia N, Bugna J, Bellabarba M, Kraft D, Coviello S, Ferolla FM, Chen A, London SJ, **Siberry GK**, Williams JV, Polack FP. A mechanistic role for type III interferon- $\lambda$ 1 in asthma exacerbations mediated by human rhinoviruses. *American Journal of Respiratory and Critical Care Medicine* 2012;185(5):508-16.
46. Rice ML, Buchanan AL, **Siberry GK**, Malee KM, Zeldow B, Frederick T, Purswani MU, Hoffman HJ, Sirois PA, Smith R, Torre P 3rd, Allison SM, Williams PL; for the Pediatric HIV/AIDS Cohort Study. Language Impairment in Children Perinatally Infected with HIV Compared With Children Exposed and Without Infection. *J Dev Behav Pediatr*. 2012;33(2):112-123.
47. **Siberry GK**, Harris DR, Oliveira RH, Krauss MR, Hofer CB, Tiraboschi AA, Marques H, Succi RC, Abreu T, Della Negra M, Mofenson LM, Hazra R. Evaluation of viral load thresholds for predicting new WHO Stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 2012; 60(2):214-8.
48. **Siberry GK**, Williams PL, Mendez H, Seage GR, Jacobson DL, Hazra R, Rich KC, Griner R, Tassiopoulos K, Kacanek D, Mofenson LM, Miller T, DiMeglio LA, Watts DH. Safety of Tenofovir Use During Pregnancy: Early Growth Outcomes in HIV-Exposed Uninfected Infants. *AIDS* 2012; 26(9):1151-9.
49. Torre P 3rd, Zeldow B, Hoffman HJ, Buchanan A, **Siberry GK**, Rice M, Sirois PA, Williams PL; for the Pediatric HIV/AIDS Cohort Study. Hearing Loss in Perinatally Human Immunodeficiency Virus-Infected and Human Immunodeficiency Virus – Exposed but Uninfected Children and Adolescents. *Pediatr Infect Dis J*. 2012; 31(8):835-841.
50. Flynn PM, Nachman S, Muresan P, Fenton T, Spector SA, Cunningham CK, Pass R, Yogev R, Burchett S, Heckman B, Bloom A, Utech LJ, Anthony P, Petzold E, Levy W, **Siberry GK**, Ebiasah R, Miller J, Handelsman E, Weinberg A; for the IMPAACT P1088 Team. Safety and Immunogenicity of 2009 Pandemic H1N1 Influenza Vaccination in Perinatally HIV-1 Infected Children and Youth. *J Infect Dis*. 2012; 206(3):421-430.
51. Lujan-Zilbermann J, Warshaw MG, Williams PL, Spector SA, Decker MD, Abzug MJ, Heckman B, Manzella A, Kabat B, Jean-Philippe P, Nachman S, **Siberry GK**; International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team. Immunogenicity and Safety of 1 vs 2 Doses of Quadrivalent Meningococcal Conjugate Vaccine in Youth Infected with Human Immunodeficiency Virus. *J Pediatr*. 2012;161(4):676-81.
52. Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Ceriotta M, Machado D, Bethel J, Morgado MG, Dickover R, Camarca M, Mirochnick M, **Siberry**



- G**, Grinsztejn B, Moreira RI, Bastos FI, Xu J, Moya J, Mofenson LM; for the NICHD HPTN 040/PACTG 1043 Protocol Team. Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection. *N Engl J Med* 2012; 366:2368-2379.
53. Wong FL, Hsu AJ, Pham PA, **Siberry GK**, Hutton N, Agwu AL. Antiretroviral Treatment Strategies in Highly Treatment Experienced Perinatally HIV-Infected Youth. *Pediatr Infect Dis J.* 2012; 31(12):1279-1283.
54. **Siberry GK**, Frederick T, Emmanuel P, Paul ME, Bohannon B, Wheeling T, Barton T, Rathore MH, Dominguez KL. Methicillin-Resistant *Staphylococcus aureus* Infections in Human Immunodeficiency Virus-Infected Children and Adolescents. *AIDS Res Treat.* 2012; 2012:627974.
55. Tassiopoulos K, Moscicki AB, Mellins C, Kacanek D, Malee K, Allison S, Hazra R, **Siberry GK**, Smith R, Paul M, Van Dyke RB, Seage GR 3rd; for the Pediatric HIV/AIDS Cohort Study. Sexual Risk Behavior Among Youth With Perinatal HIV Infection in the United States: Predictors and Implications for Intervention Development. *Clin Infect Dis.* 2013 Jan;56(2):283-290.
56. Dimeglio LA, Wang J, **Siberry GK**, Miller TL, Geffner ME, Hazra R, Borkowsky W, Chen JS, Dooley L, Patel K, van Dyke RB, Fielding RA, Gurmu Y, Jacobson DL; for the Pediatric HIV/AIDS Cohort Study (PHACS). BMD in Children and Adolescents with HIV Bone Mineral Density in Children and Adolescents with Perinatal HIV Infection. *AIDS.* 2013 Jan 14;27(2):211-20.
57. Wilkinson JD, Williams PL, Leister E, Zeldow B, Shearer WT, Colan SD, **Siberry GK**, Dooley LB, Scott GB, Rich KC, Lipshultz SE; for the Pediatric HIV/AIDS Cohort Study (PHACS). Cardiac Biomarkers in HIV-Exposed Uninfected Children: The Pediatric HIV/AIDS Cohort Study (PHACS). *AIDS.* 2013;27(7):1099-108.
58. Hosek S, **Siberry G**, Bell M, Lally M, Kapogiannis B, Green K, Fernandez MI, Rutledge B, Martinez J, Garofalo R, Wilson C; the Adolescent Trials Network for HIV/AIDS Interventions (ATN). The Acceptability and Feasibility of an HIV Pre-Exposure Prophylaxis (PrEP) Trial with Young Men who Have Sex with Men (YMSM). *J Acquir Immune Defic Syndr.* 2013;62(4):447-56.
59. Purswani M, Patel K, Kopp JB, Seage GR 3rd, Chernoff MC, Hazra R, **Siberry GK**, Mofenson LM, Scott GB, Van Dyke RB; for the Pediatric HIV/AIDS Cohort Study. Tenofovir Treatment Duration Predicts Proteinuria in a Multi-Ethnic United States Cohort of Children and Adolescents with Perinatal HIV-1 Infection. *Pediatr Infect Dis J.* 2013;32(5):495-500.
60. Joao E, Gouvea MI, Freimanis-Hance L, Cohen RA, Read JS, Melo V, Duarte G, Ivalo S, Machado DM, Pilotto J, **Siberry GK**; for the NISDI/LILAC Protocol. Institutional prevention policies and rates of Group B Streptococcus infection among HIV-infected pregnant women and their infants in Latin America. *Int J*

*Gynaecol Obstet.* 2013;120(2):144-147.

61. Weinberg A, Muresan P, Fenton T, Richardson K, Dominguez T, Bloom A, Petzold E, Anthony P, Cunningham C, Spector SA, Nachman S, **Siberry GK**, Handelsman E, Flynn P, Study Team FI. High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1H1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088). *Hum Vaccin Immunother.* 2013;9(5):957-968.
62. Gaur AH, Cohen RA, Read JS, Hance LF, Dominguez K, Alarcon JO, Menezes J, Peixoto MF, Mussi-Pinhata MM, Coelho DF, Mitchell C, **Siberry GK**. Prechewing and prewarming food for HIV-exposed children: A prospective cohort experience from Latin America. *AIDS Patient Care STDS.* 2013 Mar;27(3):142-5.
63. Spector SA, Qin M, Lujan-Zilbermann J, Singh KK, Warshaw MG, Williams PL, Jean-Philippe P, Fenton T, **Siberry GK** for the IMPAACT P1065 Protocol Team. Genetic variants in TLR -2, -4 and -9 and FC $\gamma$ R2 are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youth. *Clin Vaccine Immunol.* 2013 20(6):900-6.
64. Rice ML, Zeldow B, **Siberry GK**, Purswani M, Malee K, Hoffman HJ, Frederick T, Buchanan A, Sirois PA, Allison SM, Williams PL for the Pediatric HIV/AIDS Cohort Study (PHACS). Evaluation of risk for late language emergence after in utero antiretroviral drug exposure in HIV-exposed uninfected infants. *Pediatr Infect Dis J.* 2013;32(10):e406-e413.
65. Lindsey JC, Shah SK, **Siberry GK**, Jean-Philippe P, Levin MJ. Ethical Tradeoffs in Trial Design: Case Study of an HPV Vaccine Trial in HIV-Infected Adolescent Girls in Lower Income Settings. *Dev World Bioeth.* 2013;13(2):95-104.
66. Izbudak I, Chalian M, Hutton N, Baskaran V, Jordan L, **Siberry GK**, Gailloud P, Agwu AL. Perinatally HIV-infected youth presenting with acute stroke: Progression/evolution of ischemic disease on neuroimaging. *J Neuroradiol.* 2013;40(3):172-80.
67. Succi RC, Krauss MR, Harris DR, Machado DM, de Moraes-Pinto MI, Mussi-Pinhata MM, Ruz NP, Pierre RB, Kolevic L, Joao E, Foradori I, Hazra R, **Siberry GK**; for the NISDI Pediatric Study Group 2012. Undervaccination of Perinatally HIV-infected and HIV-exposed Uninfected Children in Latin America and the Caribbean. *Pediatr Infect Dis J.* 2013;32(8):845-50.
68. Nesheim SR, Hardnett F, Wheeling JT, **Siberry GK**, Paul ME, Emmanuel P, Bohannon B, Dominguez K, for the LEGACY Consortium. Incidence of opportunistic illness before and after initiation of highly active antiretroviral therapy in children. *Pediatr Infect Dis J.* 2013;32(10):1089-1095.

70. Pass RF, Nachman S, Flynn PM, Muresan P, Fenton T, Cunningham CK, Borkowsky W, McAuley JB, Spector SA, Petzold E, Levy W, **Siberry GK**, Handelsman E, Utech LJ, Weinberg A for the IMPAACT 1089 Team. Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth. *J Pediatric Infect Dis Soc* 2013;2(4):352-360.
71. Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogeve R, Handelsman E, **Siberry GK**, Thumar B, Schappell E, Bull CV, Chu HY, Schaap-Nutt A, Buchholz U, Collins PL, Schmidt AC; the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children. *Vaccine* 2013;31(48):5706-12.
72. Ransom CE, Huo Y, Patel K, Scott GB, Watts DH, Williams P, **Siberry GK**, Livingston EG for the P1025 Team of International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. *J Acquir Immune Defic Syndr* 2013; 64(4):374-81.
73. Hosek SG, Green KR, **Siberry G**, Lally M, Balthazar C, Serrano PA, Kapogiannis B for the Adolescent Medicine Trial Network for HIV/AIDS Interventions (ATN). Integrating behavioral HIV interventions into biomedical prevention trials with youth: Lessons from Chicago's Project PrEPare *Journal of HIV/AIDS & Social Services* 2013;12:333-348.
74. **Siberry GK**, Cohen RA, Harris DR, Santos Cruz ML, Oliveira R, Peixoto MF, Cervi MC, Hazra, R, Pinto JA for the NISDI PLACES Protocol. Prevalence and predictors of elevated aspartate aminotransferase-to-platelet ratio index in Latin American perinatally HIV-infected children. *Pediatr Infect Dis J.* 2014;33(2):177-82.
75. Patel K, Wang J, Jacobson DL, Lipshultz SE, Landy DC, Geffner ME, Dimeglio LA, Seage GR 3rd, Williams PL, van Dyke RB, **Siberry GK**, Shearer WT, Young L, Scott GB, Wilkinson JD, Fisher SD, Starc TJ, Miller TL. Aggregate Risk of Cardiovascular Disease among Adolescents Perinatally Infected with the Human Immunodeficiency Virus. *Circulation* 2014 129(11):1204-12.
76. Machado ES, Krauss MR, Megazzini K, Coutinho CM, Kreitchmann R, Melo VH, Pilotto JH, Ceriotto M, Hofer CB, **Siberry GK**, Watts DH; for the NICHD International Site Development Initiative (NISDI) Pediatric Protocol. Hypertension, preeclampsia and eclampsia among HIV-infected pregnant women from Latin America and Caribbean countries. *J Infect* 2014;68(6):572-80.
77. Kreitchmann R, Li SX, Melo VH, Fernandes Coelho D, Watts DH, Joao E, Coutinho CM, Alarcon JO, **Siberry GK**. Predictors of adverse pregnancy outcomes in women

- infected with HIV in Latin America and the Caribbean: a cohort study. *BJOG* 2014; DOI:10.1111/1471-0528.12680.
78. Okelo SO, **Siberry GK**, Solomon BS, Bilderback AL, Yamazaki M, Hetzler T, Ferrell CL, Dhepyasuwan N, Serwint JR; CORNET Investigators. Asthma Treatment Decisions by Pediatric Residents Do Not Consistently Conform to Guidelines or Improve With Level of Training. *Acad Pediatr*. 2014;14(3):287-93..
  79. **Siberry GK**, Patel K, Pinto JA, Puga A, Mirza A, Miller TL, Van Dyke RB for the Pediatric HIV/AIDS Cohort Study (PHACS). Elevated aspartate aminotransferase-to-platelet ratio index in perinatally HIV-infected children in the United States. *Pediatr Infect Dis J*. 2014, 33(8):855-7.
  80. Persaud D, Patel K, Karalius B, Rainwater-Lovett K, Ziemniak C, Ellis A, Chen YH, Richman D, **Siberry GK**, Van Dyke RB, Burchett S, Seage GR 3rd, Luzuriaga K; for the Pediatric HIV/AIDS Cohort Study. Influence of Age at Virologic Control on Peripheral Blood Human Immunodeficiency Virus Reservoir Size and Serostatus in Perinatally Infected Adolescents. *JAMA Pediatr*. 2014;168(12):1138-1146.
  81. Brady TM, Neu AM, Miller ER 3rd, Appel LJ, **Siberry GK**, Solomon BS. Real-Time Electronic Medical Record Alerts Increase High Blood Pressure Recognition in Children. *Clin Pediatr (Phila)*. 2015;54(7):667-75.
  82. Monteiro JP, Cruz ML, Mussi-Pinhata MM, Salomão RG, Jordão Junior A, Read JS, Pilotto JH, Cohen RA, Stoszek SK, **Siberry GK**. Vitamin A, vitamin E, iron and zinc status in a cohort of HIV-infected mothers and their uninfected infants. *Rev Soc Bras Med Trop*. 2014;47(6):692-700.
  83. Lipshultz SE, Williams PL, Zeldow B, Wilkinson JD, Rich KC, van Dyke RB, Seage GR 3rd, Dooley LB, Kaltman JR, **Siberry GK**, Mofenson LM, Shearer WT, Colan SD; Pediatric HIV/AIDS Cohort Study (PHACS). Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers. *AIDS*. 2015;29(1):91-100.
  84. Torre P 3rd, Yao TJ, Zeldow B, Williams P, Hoffman HJ, **Siberry GK**; Pediatric HIV/AIDS Cohort Study (PHACS). Distortion product otoacoustic emission data in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents in the Pediatric HIV/AIDS Cohort Study. *Pediatr Infect Dis J*. 2015 ;34(3):276-8.
  85. Jao J, Freimanis L, Mussi-Pinhata MM, Cohen RA, Monteiro JP, Cruz ML, Sperling RS, Branch A, **Siberry GK**; NISDI LILAC Protocol. Low vitamin D status among pregnant Latin American and Caribbean women with HIV Infection. *Int J Gynaecol Obstet*. 2015;130(1):54-8. doi: 10.1016/j.ijgo.2015.01.017.
  86. Kreitchmann R, Coelho DF, Kakehasi FM, Hofer CB, Read JS, Losso M, Haberer JE, **Siberry GK**, Harris DR, Yu Q. Long-term postpartum adherence to antiretroviral

- drugs among women in Latin America. *Int J STD AIDS*. 2016 Apr;27(5):377-86
87. Himes SK, Wu JW, Jacobson DL, Tassiopoulos K, Hazra R, Kacanek D, Van Dyke RB, Rich KC, **Siberry GK**, Huestis MA; Pediatric HIV/AIDS Cohort Study (PHACS). Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children. *Pediatr Infect Dis J*. 2015;34(8):851-7.
  88. Himes SK, Huo Y, **Siberry GK**, Williams PL, Rice ML, Sirois PA, Frederick T, Hazra R, Huestis MA; Pediatric HIV/AIDS Cohort Study (PHACS). Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure. *J Acquir Immune Defic Syndr*. 2015;69(2):178-86.
  89. **Siberry GK**, Jacobson DL, Kalkwarf HJ, Wu JW, DiMeglio LA, Yogev R, Knapp KM, Wheeler JJ, Butler L, Hazra R, Miller TL, Seage GR 3rd, Van Dyke RB, Barr E, Davtyan M, Mofenson LM, Rich KC; Pediatric HIV/AIDS Cohort Study. Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy. *Clin Infect Dis*. 2015;61(6):996-1003.
  90. **Siberry GK**, Patel K, Bellini WJ, Karalius B, Purswani MU, Burchett SK, Meyer WA 3rd, Sowers SB, Ellis A, Van Dyke RB; Pediatric HIV/AIDS Cohort Study (PHACS); Pediatric HIV/AIDS Cohort Study PHACS. Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection. *Clin Infect Dis*. 2015;61(6):988-95.
  91. Fairlie L, Karalius B, Patel K, van Dyke RB, Hazra R, Hernán MA, **Siberry GK**, Seage GR 3rd, Agwu A, Wiznia A; Pediatric HIV/AIDS Cohort Study (PHACS), The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT). CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States. *AIDS*. 2015;29(16):2109-19.
  92. Kreitchmann R, Megazzini K, Melo VH, Coelho DF, Watts DH, Krauss M, Gouvea MI, Duarte G, Losso MH, **Siberry GK**. Repeat pregnancy in women with HIV infection in Latin America and the Caribbean. *AIDS Care*. 2015;19:1-9.
  93. Purswani MU, Karalius B, Yao TJ, Schmid DS, Burchett SK, **Siberry GK**, Patel K, Van Dyke RB, Yogev R; Pediatric HIV/AIDS Cohort Study (PHACS); Pediatric HIV/AIDS Cohort Study PHACS. Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection. *Clin Infect Dis*. 2016;62(1):106-14.
  94. Setse RW, **Siberry GK**, Moss WJ, Wheeling J, Bohannon BA, Dominguez KL; LEGACY Consortium. Meningococcal Conjugate and tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccination Among HIV-Infected Youth. *Pediatr Infect Dis J*. 2016;35(5):e152-7.

95. Kapogiannis BG, Leister E, **Siberry GK**, Van Dyke RB, Rudy B, Flynn P, Williams PL; REACH Study and the PACTG 219219C Study. Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth. *AIDS*. 2016;30(6):889-898.
96. Spaulding AB, Yu Q, Civitello L, Mussi-Pinhata M, Pinto J, Gomes IM, Alarcon J, **Siberry G**, Harris DR, Hazra R. Neurologic outcomes in HIV-exposed/uninfected infants exposed to antiretroviral drugs during pregnancy in Latin America and the Caribbean. *AIDS Res Hum Retroviruses*. 2016;32(4):349-56.
97. Agwu AL, Yao TJ, Eshleman SH, Patel K, Huang W, Burchett SK, **Siberry GK**, Van Dyke RB; Pediatric HIV/AIDS Cohort Study. Phenotypic Coreceptor Tropism in Perinatally HIV-infected Youth Failing Antiretroviral Therapy. *Pediatr Infect Dis J*. 2016;35(7):777-81.
98. Adachi K, Klausner JD, Xu J, Ank B, Bristow CC, Morgado MG, Watts DH, Weir F, Persing D, Mofenson LM, Veloso VG, Pilotto JH, Joao E, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Ceriotto M, Machado DM, Bryson YJ, Grinsztejn B, Bastos FI, **Siberry G**, Nielsen-Saines K; NICHD HPTN 040 Study Team. Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-infected Pregnant Women and Adverse Infant Outcomes. *Pediatr Infect Dis J*. 2016;35(8):894-900.
99. Aarons GA, Sommerfeld DH, Chi BH, Ezeanolue EE, Sturke R, Guay L, **Siberry GK**. Concept Mapping of PMTCT Implementation Challenges and Solutions Across 6 sub-Saharan African Countries in the NIH-PEPFAR PMTCT Implementation Science Alliance. *J Acquir Immune Defic Syndr*. 2016;72 Suppl 2:S202-6.
100. Ezeanolue EE, Powell BJ, Patel D, Olutola A, Obiefune M, Dakum P, Okonkwo P, Gobir B, Akinmurele T, Nwandu A, Torpey K, Oyeledum B, Aina M, Eyo A, Oleribe O, Ibang I, Oko J, Anyaie C, Idoko J, Aliyu MH, Sturke R, Watts H, **Siberry G**; Nigeria Implementation Science Alliance. Identifying and Prioritizing Implementation Barriers, Gaps, and Strategies Through the Nigeria Implementation Science Alliance: Getting to Zero in the Prevention of Mother-to-Child Transmission of HIV. *J Acquir Immune Defic Syndr*. 2016;72 Suppl 2:S161-6.
101. Price JT, Wheeler SB, Stranix-Chibanda L, Hosek SG, Watts DH, **Siberry GK**, Spiegel HM, Stringer JS, Chi BH. Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa. *J Acquir Immune Defic Syndr*. 2016;72 Suppl 2:S145-53.
102. Jourdain G, Ngo-Giang-Huong N, Cressey TR, Hua L, Harrison L, Tierney C, Salvadori N, Decker L, Traisathit P, Sirirungsi W, Khamduang W, Bowonwatanuwong C, Puthanakit T, **Siberry GK**, Watts DH, Murphy TV, Achalapong J, Hongsiriwon S,

- Klinbuayaem V, Thongsawat S, Chung RT, Pol S, Chotivanich N. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. *BMC Infect Dis.* 2016;16:393.
103. Hosek S, Rudy B, Landovitz R, Kapogiannis B, **Siberry G**, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G, Lally M, Mayer K, Anderson P, Kiser J, Rooney J, Wilson CM; Adolescent Trials Network (ATN) for HIV/AIDS Interventions. An HIV Pre-Exposure Prophylaxis (PrEP) Demonstration Project and Safety Study for Young MSM. *J Acquir Immune Defic Syndr.* 2017;74(1):21-29.
  104. Levin MJ, Lindsey JC, Kaplan SS, Schimana W, Lawrence J, McNeal MM, Bwakura-Dangarembizi M, Ogwu A, Mpabalwani EM, Sato P, **Siberry G**, Nelson M, Hille D, Weinberg GA, Weinberg A. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. *AIDS.* 2017 Jan 2;31(1):49-59.
  105. Jao J, Freimanis L, Mussi-Pinhata MM, Cohen RA, Monteiro JP, Cruz ML, Branch A, Sperling RS, **Siberry GK**; NISDI LILAC Protocol.. Severe Vitamin D Deficiency in Human Immunodeficiency Virus-Infected Pregnant Women is Associated with Preterm Birth. *Am J Perinatol.* 2017;34(5):486-492.
  106. Melvin AJ, Montepiedra G, Aaron L, Meyer WA 3rd, Spiegel HM, Borkowsky W, Abzug MJ, Best BM, Crain MJ, Borum PR, Graham B, Anthony P, Shin K, **Siberry GK**; P1063 Study Team.. Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-Infected Children, Adolescents and Young Adults with Hyperlipidemia. *Pediatr Infect Dis J.* 2017;36(1):53-60.
  107. Jacobson DL, Patel K, Williams PL, Geffner ME, **Siberry GK**, Dimeglio LA, Crain MJ, Mirza A, Chen JS, McFarland E, Kacanek D, Silio M, Rich K, Borkowsky W, Van Dyke RB, Miller TL; Pediatric HIV/AIDS Cohort Study.. Growth at Two Years of Age in HIV-Exposed Uninfected Children in the US by Trimester of Maternal Antiretroviral Initiation. *Pediatr Infect Dis J.* 2017; 36(2):189-197.
  108. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, McIntyre J, Gnanashanmugam D, **Siberry GK**, Coletti AS, Taha TE, Klingman KL, Martinson FE, Owor M, Violari A, Moodley D, Theron GB, Bhosale R, Bobat R, Chi BH, Strehlau R, Mlay P, Loftis AJ, Browning R, Fenton T, Purdue L, Basar M, Shapiro DE, Mofenson LM;for the IMPAACT 1077BF/1077FF PROMISE Study Team. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. *N Engl J Med* 2016; 375:1726-1737.
  109. Shepherd JA, Sommer MJ, Fan B, Powers C, Stranix-Chibanda L, Zadzilka A, Basar M, George K, Mukwasi-Kahari C, **Siberry G**. Advanced Analysis Techniques Improve Infant Bone and Body Composition Measures by Dual-Energy X-Ray Absorptiometry. *J*

*Pediatr.* 2017;181:248-253.e3.

110. Redmond SM, Yao TJ, Russell JS, Rice ML, Hoffman HJ, **Siberry GK**, Frederick T, Purswani M, Williams PL; Pediatric HIV/AIDS Cohort Study. Longitudinal Evaluation of Language Impairment in Youth With Perinatally Acquired Human Immunodeficiency Virus (HIV) and Youth With Perinatal HIV Exposure. *J Pediatric Infect Dis Soc.* 2016;5(suppl 1):S33-S40.
111. Weinberg A, Mussi-Pinhata MM, Yu Q, Cohen RA, Almeida VC, Amaral F, Pinto J, Teixeira ML, Succi RC, Freimanis L, Read JS, **Siberry G**; NISDI Perinatal, LILAC, CIRAI Protocols.. Excess respiratory viral infections and low antibody responses among HIV-exposed, uninfected infants. *AIDS.* 2017;31(5):669-679.
112. Rainwater-Lovett K, Ziemniak C, Watson D, Luzuriaga K, **Siberry G**, Petru A, Chen Y, Uprety P, McManus M, Ho YC, Lamers SL, Persaud D. Paucity of Intact Non-Induced Provirus with Early, Long-Term Antiretroviral Therapy of Perinatal HIV Infection. *PLoS One.* 2017;12(2):e0170548.
113. Lee S, **Siberry GK**, Alarcón JO, Reyes Vega M, Kolevic Roca L, Gutierrez C, Celia de Menezes Succi R, Ferreira Peixoto M, Stoszek SK, Hazra R, Harris DR. Prevalence and Associated Characteristics of HIV-Infected Children in Latin America Who Know Their HIV Status. *J Pediatric Infect Dis Soc.* 2018;7(1):78-81.
114. Shearer WT, Jacobson DL, Yu W, **Siberry GK**, Purswani M, Siminski S, Butler L, Leister E, Scott G, Van Dyke RB, Yogev R, Paul ME, Puga A, Colin AA, Kattan M; Pediatric HIV/AIDS Cohort Study.. Long-Term Pulmonary Complications in Perinatally HIV-Infected Youth. *J Allergy Clin Immunol.* 2017;140(4):1101-1111.
115. Huo Y, Patel K, Scott GB, Van Dyke RB, **Siberry GK**, Burchett SK, Shearer WT. Lymphocyte Subsets in HIV-Exposed Uninfected Infants and HIV-Unexposed Uninfected Infants. *J Allergy Clin Immunol.* 2017;140(2):605-608.
116. Warshaw MG, **Siberry GK**, Williams P, Decker MD, Jean-Philippe P, Lujan-Zilbermann J. Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth. *J Pediatric Infect Dis Soc.* 2017;6(3):e69-e74.
117. Smith C, Jalbert E, de Almeida V, Canniff J, Lenz LL, Mussi-Pinhata MM, Cohen RA, Yu Q, Amaral FR, Pinto J, Alarcon JO, **Siberry G**, Weinberg A. Altered Natural Killer Cell Function in HIV-Exposed Uninfected Infants. *Front Immunol.* 2017;8:470.
118. Agwu AL, Warshaw MG, McFarland EJ, **Siberry GK**, Melvin AJ, Wiznia AA, Fairlie L, Boyd S, Harding P, Spiegel HML, Abrams EJ, Carey VJ; P1094 Study Team. Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents



- living with HIV infection: Results of the IMPAACT P1094 randomized trial. *PLoS One*. 2017;12(6):e0178075.
119. Hosek SG, Landovitz RJ, Kapogiannis B, **Siberry GK**, Rudy B, Rutledge B, Liu N, Harris DR, Mulligan K, Zimet G, Mayer KH, Anderson P, Kiser JJ, Lally M, Brothers J, Bojan K, Rooney J, Wilson CM. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. *JAMA Pediatr*. 2017;171(11):1063-1071.
  120. Pinto JA, Capparelli EV, Warshaw M, Zimmer B, Cressey TR, Spector SA, Qin M, Smith B, **Siberry GK**, Mirochnick M; IMPAACT P1083 Team. A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines. *Pediatr Infect Dis J*. 2017;37(2):e29-e35.
  121. Succi RC, Krauss MR, Harris DR, Machado DM, de Moraes-Pinto MI, Mussi-Pinhata MM, Pavia Ruz N, Pierre RB, Kolevic Roca LA, Joao E, Foradori I, Scotta MC, Hazra R, **Siberry GK**; NISDI Pediatric Study Group 2012. Immunity Following Childhood Vaccinations in Perinatally HIV-Exposed Children with and without HIV Infection in Latin America. *Pediatr Infect Dis J*. 2018 37(4):304-309.
  122. Rice ML, Russell JS, Frederick T, Purswani M, Williams PL, **Siberry GK**, Redmond SM, Hoffman HJ, Yao TJ; Pediatric HIV/AIDS Cohort Study (PHACS). Risk for Speech and Language Impairments in Pre-school Aged HIV-Exposed Uninfected Children with in utero Combination Antiretroviral Exposure. *Pediatr Infect Dis J*. 2018;37(7):678-685.
  123. McFarland EJ, Karron RA, Muresan P, Cunningham CK, Valentine ME, Perlowski C, Thumar B, Gnanashanmugam D, **Siberry GK**, Schappell E, Barr E, Rexroad V, Yogev R, Spector SA, Aziz M, Patel N, Cielo M, Luongo C, Collins PL, Buchholz UJ. Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children. *The Journal of Infectious Diseases* 2018; 217(9):1347-1355.
  124. Buchholz UJ, Cunningham CK, Muresan P, Gnanashanmugam D, Sato P, **Siberry GK**, Rexroad V, Valentine M, Perlowski C, Schappell E, Thumar B, Luongo C, Barr E, Aziz M, Yogev R, Spector SA, Collins PL, McFarland EJ, Karron RA. Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children. *The Journal of Infectious Diseases* 2018; 217(9):1338-1346.
  125. Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, Salvadori N, Cressey TR, Sirirungsi W, Achalapong J, Yuthavisuthi P, Kanjanavikai P, Na Ayudhaya OP, Siriwachirachai T, Prommas S, Sabsanong P, Limtrakul A, Varadisai S, Putiyanun C, Suriyachai P, Liampongsabuddhi P, Sangsawang S, Matanasarawut W, Buranabanjasatean S, Puernngooluerm P, Bowonwatanuwong C, Puthanakit T, Klinbuayaem V, Thongsawat S, Thanprasertsuk S, **Siberry GK**, Watts DH, Chakhtoura N, Murphy TV, Nelson NP, Chung RT, Pol S, Chotivanich N. Tenofovir

- versus Placebo to Prevent Perinatal Transmission of Hepatitis B. *N Engl J Med.* 2018;378(10):911-923.
126. Weinberg A, Mussi-Pinhata M, Yu Q, Cohen RA, Almeida VC, Amaral FR, Freimanis L, Harris DR, Smith C, **Siberry G**. Factors Associated with Lower Respiratory Tract Infections in HIV-Exposed Uninfected Infants. *AIDS Res Hum Retroviruses* 2018; 34(6):527-535.
  127. Cressey TR, Harrison L, Achalapong J, Kanjanavikai P, Patamasingh Na Ayudhaya O, Liampongsabuddhi P, Siritwachirachai T, Putiyanun C, Suriyachai P, Tierney C, Salvadori N, Chinwong D, Decker L, Tawon Y, Murphy TV, Ngo-Giang-Huong N, **Siberry GK**, Jourdain G; iTAP study team. Tenofovir exposure during pregnancy and postpartum in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission of hepatitis B virus. *Antimicrob Agents Chemother.* 2018;62(12) pii: e01686-18.
  128. Hanan NJ, Paul ME, Huo Y, Kapetanovic S, Smith E, **Siberry G**, Brouwers P, Graham B, Johnston B, Capparelli EV, Best BM. Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults. *Frontiers in Pediatrics* 2019(7); <https://doi.org/10.3389/fped.2019.00016>.
  129. Salvadori N, Fan B, Teeyasoontranon W, Ngo-Giang-Huong N, Phanomcheong S, Luvira A, Puangsombat A, Suwannarat A, Srirompotong U, Putiyanun C, Cressey TR, Decker L, Khamduang W, Harrison L, Tierney C, Shepherd JA, Kourtis AP, Bulterys M, **Siberry GK**, Jourdain G. Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus. *Clin Infect Dis.* 2019;69(1):144-146.
  130. Ezeanolue EE, Iheanacho T, Patel DV, Patel S, Sam-Agudu N, Obiefune M, Dakum P, Okonkwo P, Olutola A, Khamofu H, Oyeledun B, Aliyu S, Aina M, Eyo A, Oko J, Akinmurele T, Oleribe O, Gebi U, Aliyu MH, Sturke R, **Siberry G**. Challenges and Strategies for Improving Training of Mid-Level Research Personnel in Nigeria. *Ann Glob Health.* 2019;85(1):87.
  131. Jacobson DL, Lindsey JC, Gordon C, Hazra R, Spiegel H, Ferreira F, Amaral FR, Pagano-Therrien J, Gaur A, George K, Benson J, **Siberry GK**; IMPAACT P1076 Study Team. Alendronate improves bone mineral density in perinatally HIV-infected children and adolescents with low bone mineral density for age. *Clin Infect Dis.* 2020;71(5):1281-1288.
  132. Aizire J, Brooks KM, Mirochnick M, Flynn PM, Butler K, Kiser JJ, **Siberry GK**, Fenton T, Cababasay M, Fowler MG; PROMISE Study Team. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. *J Acquir Immune Defic Syndr.* 2020;83(2):173-180.

133. Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, Da Silva J, Raizes E, Ford N, **Siberry GK**, Gupta RK, Barnabas R, Revill P, Cohn J, Calmy A, Bertagnolio S. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. *Lancet HIV*. 2020 Mar;7(3):e193-e200.
134. João EC, Morrison RL, Shapiro DE, Chakhtoura N, Gouvêa MIS, de Lourdes B Teixeira M, Fuller TL, Mmbaga BT, Ngocho JS, Njau BN, Violari A, Mathiba R, Essack Z, Pilotto JHS, Moreira LF, Rolon MJ, Cahn P, Prommas S, Cressey TR, Chokephaibulkit K, Werarak P, Laimon L, Hennessy R, Frenkel LM, Anthony P, Best BM, **Siberry GK**, Mirochnick M. . Raltegravir versus efavirenz in antiretroviral-naïve pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial. *Lancet HIV*. 2020;7(5): e322-e331.
135. Ezeanolue EE, Iheanacho T, Adedeji IA, Itanyi IU, Olakunde B, Patel D, Dakum P, Okonkwo P, Akinmurele T, Obiefune M, Khamofu H, Oyeledun B, Aina M, Eyo A, Oleribe O, Oko J, Olutola A, Gobir I, Aliyu MH, Aliyu G, Woelk G, Aarons G, **Siberry G**, Sturke R; Nigeria Implementation Science Alliance. Opportunities and challenges to integrating mental health into HIV programs in a low- and middle-income country: insights from the Nigeria implementation science Alliance. *BMC Health Serv Res*. 2020;20(1):904.
136. Lindsey JC, Jacobson DL, Spiegel H, Gordon CM, Hazra R, **Siberry GK**; IMPAACT P1076 Study Team. Safety and efficacy of 48 and 96 weeks of alendronate in children and adolescents with perinatal HIV infection and low bone mineral density for age. *Clin Infect Dis*. 2021;72(6):1059-1063. doi: 10.1093/cid/ciaa861. PMID: 32584996; PMCID: PMC7958836.
137. Stranix-Chibanda L, Tierney C, Sebikari D, Aizire J, Dadabhai S, Zanga A, Mukwasi-Kahari C, Vhembo T, Violari A, Theron G, Moodley D, George K, Fan B, Sommer MJ, Browning R, Mofenson LM, Shepherd J, Nelson B, Fowler MG, **Siberry GK**; PROMISE P1084s study team. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. *PLoS One*. 2021;16(2):e0246272.
138. Stranix-Chibanda L, Tierney C, Pinilla M, George K, Aizire J, Chipoka G, Mallewa M, Naidoo M, Nematadzira T, Kusakara B, Violari A, Mbengeranwa T, Njau B, Fairlie L, Theron G, Mubiana-Mbewe M, Khadse S, Browning R, Fowler MG, **Siberry GK**; PROMISE Study Team. Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial. *PLoS One*. 2021;16(8):e0255250. doi: 10.1371/journal.pone.0255250. PMID: 34415933; PMCID: PMC8378741.

139. Bailey LE, **Siberry GK**, Agaba P, Douglas M, Clinkscales JR, Godfrey C. The impact of COVID-19 on multi-month dispensing (MMD) policies for antiretroviral therapy (ART) and MMD uptake in 21 PEPFAR-supported countries: a multi-country analysis. *J Int AIDS Soc.* 2021;24 Suppl 6(Suppl 6):e25794. doi: 10.1002/jia2.25794. PMID: 34713578; PMCID: PMC8554217.
140. Stanic T, McCann N, Penazzato M, Flanagan C, Essajee S, Freedberg KA, Doherty M, Putta N, Myer L, **Siberry GK**, Collins IJ, Vojnov L, Abrams E, Soeteman DI, Ciaranello AL. Cost-effectiveness of Routine Provider-Initiated Testing and Counseling for Children With Undiagnosed HIV in South Africa. *Open Forum Infect Dis.* 2021;5;9(1):ofab603. doi: 10.1093/ofid/ofab603. PMID: 35028333; PMCID: PMC8753042.
141. Baltrusaitis K, Makanani B, Tierney C, Fowler MG, Moodley D, Theron G, Nyakudya LH, Tomu M, Fairlie L, George K, Heckman B, Knowles K, Browning R, **Siberry GK**, Taha TE, Stranix-Chibanda L; PROMISE P1084s Study Team. Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial. *BMC Infect Dis.* 2022;22(1):634. doi: 10.1186/s12879-022-07608-8. PMID: 35858874; PMCID: PMC9297643.
142. Hrapcak S, Hast M, Okegbe T, Gross J, Williams J, Patel M, Wolf H, **Siberry G**, Lee L, Wiersma S, Agaba P, Carpenter D, Rivadeneira E; PEPFAR Adolescent Group. The status of adolescent testing and treatment in PEPFAR-supported programs, October 2017-September 2020. *J Acquir Immune Defic Syndr.* 2023 Jan 30. doi: 10.1097/QAI.0000000000003166. Epub ahead of print. PMID: 36716723.

### Invited Editorials & Journal Supplements

1. **Siberry GK**, Joyner M, Hutton N. Growing up with perinatal HIV infection: Time for a HAART to heart. *J Pediatr* 2008;153:456-7.
2. **Siberry GK**, Tindyebwa D. Commentary: When to start and what to use in children - Recommendations and rationale. *AIDS* 2014, 28 Suppl 2:S133-5.
3. Supplement Co-editor. Infections Transmitted From Mother to Child During Pregnancy, Delivery, and Breastfeeding. *Journal of the Pediatric Infectious Disease Society (JPIDS)* 2014;3(1): S1-40. [http://jpid.oxfordjournals.org/content/3/suppl\\_1.toc](http://jpid.oxfordjournals.org/content/3/suppl_1.toc)
4. Supplement Co-editor. Advancing Implementation Science in Prevention of Maternal-Child HIV Transmission. Sturke R, **Siberry G**, co-editors. *J Acquir Immune Defic Syndr.* 2016 Aug 1;72 Suppl 2.
5. Rakhmanina N, **Siberry GK**. In Search of the Right Time and Right Place: Screening Adolescents and Youth for Human Immunodeficiency Virus in the United States. *J Adolesc Health.* 2018; 62(1):3-4.

6. **Siberry GK.** Beyond Prevention of Vertical HIV Transmission – Improving Outcomes of HIV-Uninfected Infants Born to Mothers with HIV Infection. *Pediatr Infect Dis J.* 2018;37(3):245.
7. Supplement Co-Editor: Post-program Learning and Knowledge from the Accelerating Children’s HIV/AIDS Treatment (ACT) Initiative. **Siberry GK**, Amzel A, Watts DH, Ahmed S. *J Acquir Immune Defic Syndr.* 2018;78 Suppl 2: S63-S146.  
<https://journals.lww.com/jaids/Pages/issuelist.aspx>
8. **Siberry GK**, Amzel A, Watts DH, Ahmed S. Supplement Introduction: Accelerating Children's HIV/AIDS Treatment (ACT) Initiative: Using What We Learned to Maintain the Pace to Close the Pediatric HIV Treatment Gap (Supplement Introduction). *J Acquir Immune Defic Syndr.* 2018;78 Suppl 2:S63-S64.
9. Supplement Co-Editor. Mind the Gap: Filling Knowledge Gaps in Paediatric and Adolescent HIV for an AIDS Free Generation. Bekker LG and **Siberry GK**, . *J Acquir Immune Defic Syndr.* 2018;78 Suppl 1:S1-S62.  
<https://journals.lww.com/jaids/toc/2018/08151>
10. Bekker LG, **Siberry GK**, Hirschall G. Ensuring Children and Adolescents Are Not Left Behind (Supplement Introduction). *J Acquir Immune Defic Syndr.* 2018 Aug 15;78 Suppl 1:S1-S2.
11. Powis KM, **Siberry GK**. Optimising HIV antiretrovirals for mothers and infants. *Lancet HIV.* 2019 May;6(5):e272-e273.
12. **Siberry GK**, Reddy UM, Mofenson LM. SARS-COV-2 Maternal-Child Transmission: Can It Occur Before Delivery and How Do We Prove It? *Pediatr Infect Dis J.* 2020 Sep;39(9):e263-e264.
13. **Siberry GK.** Keeping Your Diagnostic Mind Open During the COVID-19 Pandemic. *Pediatr Infect Dis J.* 2020;39(12):e444

#### **Review Articles**

1. **Siberry GK**, Cohen BA, and Johnson B. Cutaneous polyarteritis nodosa. *Arch Dermatol* 1994;130(7):884-889.
2. **Siberry GK.** Complications of influenza infection in children. *Pediatr Ann* 2000;29(11): 683-690.
3. **Siberry GK**, Ruff A, Black R. Zinc and human immunodeficiency virus infection. *Nutr Res* 2002;22(4):527-38.

4. **Siberry GK.** Papular-purpuric gloves and socks syndrome due to acute parvovirus B19 infection: case report and review [Clinical Insights, Contemporary Topics]. MD Consult Infectious Disease. October 1, 2003. Available at: <http://www.mdconsult.com>.
5. **Siberry GK,** Parsons G, Hutton N. Management of infants born to HIV infected mothers. *The Hopkins HIV Report* 2003;15(6):7-9,12.
6. **Siberry GK,** Carroll KC. In vitro inducible clindamycin resistance in *Staphylococcus aureus*. ASCP Tech Sample Microbiology No. MB-3, pp. 19-23.
7. **Siberry GK.** Fighting a rising ride of MRSA in the young. *Contemporary Pediatrics* 2005; 22(7): 1-10.
8. Chandran A, Heinzen RR, Santosham M, **Siberry GK.** Nosocomial Rotavirus Infections: A systematic review. *J Pediatr.* 2006;149(4):441-7.
9. Bhat N, **Siberry GK.** Influenza in infants and children. *eInfluenza Review*, Bartlett JG, Farley JE, eds., May 2007.
10. Singh HK, Gupta A, **Siberry GK,** Gupte N, Sastry J, Kinikar A, Shah I, Gangakhedkar RR, Bollinger RC, Kulkarni V. The Indian Pediatric HIV Epidemic: a Systematic Review. *Curr HIV Res.* 2008 Sep;6(5):419-32..
11. Brady TM, **Siberry GK,** Solomon BS. Pediatric hypertension: A review of proper screening, diagnosis, evaluation, and treatment. *Contemporary Pediatrics* 2008;25(11):46-56.
14. Simpkins EP, **Siberry GK,** Hutton N. If you don't think about it, you won't look for it: HIV infection in children and adolescents. *Pediatrics in Review* 2009; 30:337-49.
15. Mofenson LM, Oleske J, Serchuck L, Van Dyke R, Wilfert C. Recommendations from the Centers for Disease Control, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, and the Pediatric Infectious Diseases Society. Guidelines for Prevention and Treatment of Opportunistic Infections among HIV-Exposed and HIV-Infected Children, *Morbidity and Mortality Weekly Report* (MMWR) August 26, 2009;58:1-166. [Served as member of working group who authored this document.]
16. Hazra R, **Siberry G,** Mofenson LM. Growing up with HIV: Children, Adolescents and Young Adults with Perinatally-Acquired HIV Infection. *Annual Review of Medicine* 2010; 61:169-85.
17. Pace JE, **Siberry GK,** Hazra R, Kapogiannis BG. Pre-Exposure Prophylaxis (PrEP) for Adolescents and Young Adults at Risk for HIV Infection: Is an Ounce of Prevention Worth a Pound of Cure? *Clin Infect Dis.* 2013;56(8):1149-55.

18. Puthanakit T, **Siberry GK**. Bone health in children and adolescents with perinatal HIV Infection. *J Int AIDS Soc*. 2013;16:18575 (1-10).
19. **Siberry GK** (Executive Secretary), Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, Mofenson LM, Nesheim S; and the Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children (Bhattacharya D; Bohannon B; Clarke D.; Edwards KM; Esbenshade JC; Flynn P; Gaur A; Gigliotti F; Harrison G; Hobbs CV; Kimberlin D; Kleiman MB; Koumans EH; Kroger A; Levin MJ; Mack CL; Marais BJ; Maron G; McAuley J; Menzies HJ; Moscicki A; Narkewicz MR; Rutstein R; Seward J; Shimamura M; Steinbach WJ; Wilson GJ). Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. *Pediatr Infect Dis J*. 2013; 32 (Supplement 2): i-KK4.
20. **Siberry GK**. Preventing and Managing HIV Infection in Infants, Children and Adolescents in the United States. *Pediatrics in Review* 2014;35(7):268-86.
21. Sturke R, Harmston C, Simonds RJ, Mofenson LM, **Siberry GK**, Watts DH, McIntyre J, Anand N, Guay L, Castor D, Brouwers P, Nagel JD. A Multi-Disciplinary Approach to Implementation Science: The NIH-PEPFAR PMTCT Implementation Science Alliance. *J Acquir Immune Defic Syndr*. 2014;67 Suppl 2:S163-7.
22. Munoz FM, Weisman LE, Read JS, **Siberry G**, Kotloff K, Friedman J, Higgins RD, Hill H, Seifert H, Nesin M. Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy. *Clin Infect Dis*. 2014;59 Suppl 7:S415-27.
23. Ford N, Meintjes G, Pozniak A, Bygrave H, Hill A, Peter T, Davies MA, Grinsztejn B, Calmy A, Kumarasamy N, Phanuphak P, deBeaudrap P, Vitoria M, Doherty M, Stevens W, **Siberry GK**. The future role of CD4 cell count for monitoring antiretroviral therapy. *Lancet Infect Dis*. 2015;15(2):241-7.
24. Allison SM, **Siberry GK**. National Institutes of Health investment in studies of HIV disclosure to children. *AIDS*. 2015;29 Suppl 1:S109-18.
25. Essajee S, Vojnov L, Penazzato M, Jani I, **Siberry GK**, Fiscus SA, Markby J. Reducing mortality in HIV-infected infants and achieving the 90-90-90 target through innovative diagnosis approaches. *J Int AIDS Soc*. 2015;18(7 Suppl 6):20299.
26. Barlow-Mosha L, Musiime V, Davies MA, Prendergast AJ, Musoke P, **Siberry G**, Penazzato M. Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation. *J Int AIDS Soc*. 2017;20(1):1-7.

27. Sturke R, **Siberry G**, Mofenson L, Watts DH, McIntyre JA, Brouwers P, Guay L. Creating Sustainable Collaborations for Implementation Science: The Case of the NIH-PEPFAR PMTCT Implementation Science Alliance. *J Acquir Immune Defic Syndr.* 2016;72 Suppl 2:S102-7.
28. **Siberry GK**, Amzel A, Ramos A, Rivadeneira ED. Impact of Human Immunodeficiency Virus Drug Resistance on Treatment of Human Immunodeficiency Virus Infection in Children in Low- and Middle-Income Countries. *J Infect Dis.* 2017 216(suppl\_9):S838-S842.
29. Beste S, Essajee S, **Siberry G**, Hannaford A, Dara J, Sugandhi N, Penazzato M. Optimal Anti-Retroviral Prophylaxis in Infants At High-Risk of Acquiring Human Immunodeficiency Virus: A Systematic Review. *Pediatr Infect Dis J.* 2018;37(2):169-175.
30. Clarke DF, Penazzato M, Capparelli E, Cressey TR, **Siberry G**, Sugandhi N, Mirochnick M; WHO Paediatric Antiretroviral Working Group. Prevention and Treatment of HIV Infection in Neonates: Evidence Base for Existing WHO Dosing Recommendations and Implementation Considerations. *Expert Rev Clin Pharmacol* 2018;11(1):83-93.
31. Penazzato M, Lewis L, Watkins M, Prabhu V, Pascual F, Auton M, Kreft W, Morin S, Vicari M, Lee J, Jamieson D, **Siberry GK**. Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries. *J Int AIDS Soc.* 2018 Feb;21 Suppl 1. doi: 10.1002/jia2.25049.
32. Ehrenkranz PD, Calleja JM, El-Sadr W, Fakoya AO, Ford N, Grimsrud A, Harris KL, Jed SL, Low-Beer D, Patel SV, Rabkin M, Reidy WJ, Reinisch A, **Siberry GK**, Tally LA, Zulu I, Zaidi I. A pragmatic approach to monitor and evaluate implementation and impact of differentiated ART delivery for global and national stakeholders. *J Int AIDS Soc.* 2018;21(3) doi: 10.1002/jia2.25080.
33. Penazzato M, Watkins M, Morin S, Lewis L, Pascual F, Vicari M, Lee J, Hargreaves S, Doherty M, **Siberry GK**. Catalysing the development and introduction of paediatric drug formulations for children living with HIV: a new global collaborative framework for action. *Lancet HIV.* 2018 May;5(5):e259-e264.
34. Medley AM, Hrapcak S, Golin RA, Dziuban EJ, Watts H, **Siberry GK**, Rivadeneira ED, Behel S. Strategies for Identifying and Linking HIV-Infected Infants, Children, and Adolescents to HIV Treatment Services in Resource Limited Settings. *J Acquir Immune Defic Syndr.* 2018 Aug 15;78 Suppl 2:S98-S106.
35. Kapogiannis BG, Nelson RM, **Siberry GK**, Lee S, Hazra R. Advancing HIV Biomedical Prevention Research for At-Risk Adolescents. *J Acquir Immune Defic Syndr.* 2018; 15;79(5):535-542.



36. Indolfi G, Easterbrook P, Dusheiko G, **Siberry G**, Chang MH, Thorne C, Bulterys M, Chan PL, El-Sayed MH, Giaquinto C, Jonas MM, Meyers T, Walsh N, Wirth S, Penazzato M. Hepatitis B virus infection in children and adolescents. *Lancet Gastroenterol Hepatol*. 2019;4(6):466-476.
37. Indolfi G, Easterbrook P, Dusheiko G, El-Sayed MH, Jonas MM, Thorne C, Bulterys M, **Siberry G**, Walsh N, Chang MH, Meyers T, Giaquinto C, Wirth S, Chan PL, Penazzato M. Hepatitis C virus infection in children and adolescents. *Lancet Gastroenterol Hepatol*. 2019;4(6):477-487.
38. Mofenson LM, Pozniak AL, Wambui J, Raizes E, Ciaranello A, Clayden P, Ehrenkranz P, Fakoya A, Hill A, Khoo S, Mahaka I, Modi S, Moore C, Phillips A, **Siberry G**, Sikwese K, Thorne C, Watts HD, Doherty M, Ford NP. Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. *J Int AIDS Soc*. 2019;22(7):e25352.
39. Alemnji G, Pati R, Chun H, Zeh C, Mosha F, **Siberry G**, Ondo P. Clinical/Laboratory Interface Interventions to Improve Impact of Viral Load and Early Infant Diagnosis Testing Scale-Up. *AIDS Res Hum Retroviruses*. 2020;36(7):550-555.
40. Wilkinson L, **Siberry GK**, Golin R, Phelps BR, Wolf HT, Modi S, Grimsrud A. Children and their families are entitled to the benefits of differentiated ART delivery. *J Int AIDS Soc*. 2020;23(4):e25482.
41. Golin R, Godfrey C, Firth J, Lee L, Minior T, Phelps BR, Raizes EG, Ake JA, **Siberry GK**. PEPFAR's response to the convergence of the HIV and COVID-19 pandemics in Sub-Saharan Africa. *J Int AIDS Soc*. 2020;23(8):e25587.
42. Vrazo AC, Golin R, Fernando NB, Killam WP, Sharifi S, Phelps BR, Gleason MM, Wolf HT, **Siberry GK**, Srivastava M. Adapting HIV services for pregnant and breastfeeding women, infants, children, adolescents and families in resource-constrained settings during the COVID-19 pandemic. *J Int AIDS Soc*. 2020;23(9):e25622.
43. Golin R, Samuel JM, Phelps BR, Persaud U, Malati CY, **Siberry GK**. The promise of paediatric dolutegravir. *J Int AIDS Soc*. 2021(1):e25660.
44. Abrams EJ, Mofenson LM, Pozniak A, Lockman S, Colbers A, Belew Y, Clayden P, Mirochnick M, **Siberry GK**, Ford N, Khoo S, Renaud F, Vitoria M, Venter WDF, Doherty M, Penazzato M; PADO and CADO Experts Groups. Enhanced and Timely Investigation of ARVs for Use in Pregnant Women. *J Acquir Immune Defic Syndr*. 2021;86(5):607-615. doi: 10.1097/QAI.0000000000002597. PMID: 33298793.
45. Holtzman CW, Godfrey C, Ismail L, Raizes E, Ake JA, Tefera F, Okutoyi S, **Siberry GK**. PEPFAR's Role in Protecting and Leveraging HIV Services in the COVID-19

Response in Africa. *Curr HIV/AIDS Rep.* 2022;1–11. doi: 10.1007/s11904-021-00587-6. PMID: 34982406; PMCID: PMC8724594.

46. Emmanuel PJ, Mansfield J, **Siberry GK**. HIV Infection: An Update for Pediatricians. *Pediatrics in Review* 2022; 43(6):335-346. doi: 10.1542/pir.2020-001644. PMID: 35641447.
47. Abrams EJ, Calmy A, Fairlie L, Mahaka IC, Chimula L, Flynn PM, Kinuthia J, Myer L, Khoo SH, Musoke P, Zwierski S, Zech JM, Lockman S, **Siberry GK**. Approaches to accelerating the study of new antiretrovirals in pregnancy. *J Int AIDS Soc.* 2022;25 Suppl 2(Suppl 2):e25916. doi: 10.1002/jia2.25916. PMID: 35851757; PMCID: PMC9294864.
48. Penazzato M, Kasirye I, Ruel T, Mukui I, Bekker A, Archary M, Musoke P, Essajee S, **Siberry GK**, Mahy M, Simnoue D, Simione B, Zech JM, Mushavi A, Abrams EJ; PNP meeting participants. Antiretroviral postnatal prophylaxis to prevent HIV vertical transmission: present and future strategies. *J Int AIDS Soc.* 2023;26(2):e26032. doi: 10.1002/jia2.26032. PMID: 36808699; PMCID: PMC9939941.

### Book Chapters

1. Iannone R and **Siberry GK**, eds. *The Harriet Lane Handbook*, 15<sup>th</sup> edition, Mosby-Year Book, Inc., 2000, Baltimore.
2. **Siberry GK**. Varicella, in *Primary Pediatric Care*, 4<sup>th</sup> edition, Hoekelman RA, Adam HM, Nelson NM, Weitzman ML, Wilson MH, eds., pp. 1385-92, Mosby, 2001, Philadelphia.
3. **Siberry GK** and Steinhoff MC. Neonatal sepsis and infections, in *Reese and Betts' A Practical Approach to Infectious Diseases*, 5<sup>th</sup> edition, Betts RF, Chapman SW and Penn RL, eds., pp. 67-96, Lippincott Williams & Williams, 2003, Philadelphia.
4. **Siberry GK** and Gray R. Neurologic complications of HIV infection in children. In: *Treatment of Pediatric Neurologic Disorders*. Singer HS, Kossoff EH, Hartman AL, Crawford TO, eds., Taylor and Francis Group, 2005, New York.
5. **Siberry GK**. Parvovirus, in *Red Book: 2006. Report of the Committee on Infectious Diseases* 27<sup>th</sup> edition. Pickering LK, et al. American Academy of Pediatrics: 2006.
6. Laufer M and **Siberry GK**. Gastrointestinal Illness, in *Comprehensive Pediatric Hospital Medicine*. Zaoutis LB, Chiang VW, eds., Elsevier, 2007, Philadelphia.
7. **Siberry GK** and Dumler JS. Spotted Fever Group Rickettsioses, in *Nelson Textbook of Pediatrics*, 18<sup>th</sup> edition, Kliegman RM, Behrman RE, Jenson HB and Stanton BF, eds. Elsevier Saunders, 2007, Philadelphia.
8. **Siberry GK** and Dumler JS. Ehrlichioses and Anaplasmosis, in *Nelson Textbook of*

- Pediatrics, 18<sup>th</sup> edition, Kliegman RM, Behrman RE, Jenson HB and Stanton BF, eds. Elsevier Saunders, 2007, Philadelphia.
9. Dumler JS and **Siberry GK**. Scrub Typhus, in Nelson Textbook of Pediatrics, 18<sup>th</sup> edition, Kliegman RM, Behrman RE, Jenson HB and Stanton BF, eds. Elsevier Saunders, 2007, Philadelphia.
  10. Dumler JS and **Siberry GK**. Typhus Group Rickettsioses, in Nelson Textbook of Pediatrics, 18<sup>th</sup> edition, Kliegman RM, Behrman RE, Jenson HB and Stanton BF, eds. Elsevier Saunders, 2007, Philadelphia.
  11. Dumler JS and **Siberry GK**. Q Fever, in Nelson Textbook of Pediatrics, 18<sup>th</sup> edition, Kliegman RM, Behrman RE, Jenson HB and Stanton BF, eds. Elsevier Saunders, 2007 Philadelphia.
  12. McMillan JA, **Siberry GK**, Lee CK, Dick J, eds. *Harriet Lane Pediatric Antimicrobial Therapy Handbook* (First edition), Elsevier, 2009, Philadelphia.
  13. Weinberg GA and **Siberry GK**. Pediatric Human Immunodeficiency Virus Infection , in *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*, 7th ed, Mandell GL, Bennett JE, Dolin R, eds. Elsevier Saunders, Philadelphia, 2010.
  14. **Siberry GK** and Hazra R. Management of HIV Infection, in *Principles and Practice of Pediatric Infectious Diseases*, 4<sup>th</sup> ed., Long SS, Pickering LK and Prober CG, eds. Elsevier Saunders, 2012, Philadelphia.
  15. McMillan JA, **Siberry GK**, Lee CK, Carroll K., eds. *Harriet Lane Pediatric Antimicrobial Therapy Handbook* (Second edition), Elsevier, 2013, Philadelphia.
  16. Weinberg GA and **Siberry GK**. Pediatric Human Immunodeficiency Virus Infection, in *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*, 8th ed, Mandell GL, Bennett JE, Dolin R, eds. Elsevier Saunders, Philadelphia, 2016.
  17. **Siberry GK**. Management of HIV Infection, in *Principles and Practice of Pediatric Infectious Diseases*, 5<sup>th</sup> ed., Long SS, Pickering LK and Prober CG, eds. Elsevier Saunders, 2018, Philadelphia.
  18. **Siberry GK**, Paul ME, Shearer WT. Pediatric HIV Infection, in *Middleton's Allergy: Principles and Practice*, 9th Edition, Elsevier Saunders, 2019, Philadelphia.
  19. Weinberg GA and **Siberry GK**. Pediatric Human Immunodeficiency Virus Infection, in *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*, 9th ed, Mandell GL, Bennett JE, Dolin R, eds. Elsevier Saunders, Philadelphia, 2019.

20. Griffith D, **Siberry GK**. Management of HIV Infection, in *Principles and Practice of Pediatric Infectious Diseases*, 6<sup>th</sup> ed., Long SS, Pickering LK and Prober CG, eds. Elsevier Saunders, 2022, Philadelphia.

**Extramural Sponsorship (Johns Hopkins University):**

2000: Detection of pertussis infection by pertussis PCR among children admitted with respiratory symptoms during RSV season. 2001-2003 Sponsor: Thrasher Research Fund PI: Siberry [Collaborators: Trish Perl, Alexandra Valsamakis] \$12,440 direct costs.

05/01/05 – 04/30/07 LEGACY: Longitudinal Epidemiologic Study to Gain insight into HIV and AIDS in Children and Youth. Sponsor: Centers for Disease Control and Prevention/WESTAT. PI: Siberry

7/01/05-06/30/06 Creation of a Dental Home within the Harriet Lane Clinic. Sponsor: Thomas Wilson Sanitarium Award Total direct costs: \$15,000. PI: Siberry [Collaborator: John Taylor, DDS]

7/01/06-6/30/08 Comparison of cephalexin versus clindamycin in the empiric treatment of community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) cutaneous infections Direct cost: \$25,000 Thrasher Research Fund. PI: Aaron Chen, MD. Primary Mentor: George Siberry

3/1/07-6/1/09 The Role of Human Metapneumovirus infection in asthmatic exacerbations in pediatric patients. Direct Cost: \$399,428. Thrasher Research Fund. PI: Fernando Polack, MD. Role: Co-Investigator.

11/1/06-6/30/2008 Technical Advisor for development of program content and personnel for JHPIEGO's Center of Excellence (COE) for Maternal and Child's Health (MCH) program to develop PMTCT+ services at several sites throughout Haiti. Train health coordinators on the PMTCT+ service package and ensure compliance with the package as well as get feedback from providers once program implementation has begun. Ensure that service providers have the competence and confidence they need to implement the PMTCT+ package so that program goals are attained. Award: \$62,000

06/1/06 -5/31/08 IMPAACT P1065: Phase I/II Study of Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in HIV-Infected Youth. Protocol Co-Chair: Siberry Award: \$16,350

12/1/07-11/1/2012 NICHD/Westat/IMPAACT: sub-site PI for International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) network site (consortium with Children's National Medical Center; PI: Steve Zeichner). This project deals with the identification and study of complications and novel treatment for HIV-1 infection in infants, children, adolescents and pregnant women domestically and internationally. Responsible for leading site research team to recruit patients from pediatric, adolescent and obstetric HIV clinics

at Johns Hopkins for participation in IMPAACT network studies. Additional IMPAACT roles include Co-Chair of Protocol P1065 (Safety and Immunogenicity of Conjugated Meningococcal Vaccine in HIV-Infected Youth); Complications Scientific Executive Committee Voting Member; Vice-Chair, P1075 Study of Maraviroc in HIV-Infected Children and Youth; Chair, P1076 Study of Alendronate in HIV-Infected Youth with Low Bone Mineral Density. *Turned over PI role to Jonathan Ellen when I assumed full-time NIH position in August 2008.*

**Major Research Activities and Programs (USG: National Institutes of Health, State Department – Office of the Global AIDS Coordinator, United States Agency for International Development)**

- 2008-2016 Program Officer/Medical Officer/Project Scientist (NIH/NICHD). Guidance to applicants and development of initiatives and to build portfolio of innovative grants in areas of prevention and treatment of HIV infection and its complications, prevention and treatment of other infections in pregnant women and children, and implementation science.
- RFA-HD-12-197. Disclosure of HIV-Status to Children in Low- and Middle-Income Country Settings (R01). Funded 6 grants (one grant with additional funding from NIMH) in Ghana, Kenya, Zimbabwe, Uganda, South Africa and China. (2012)
  - RFA-HD-12-205 Disclosure of HIV-Status to Children in Low- and Middle-Income Country Settings (R21). Funded 3 grants in Haiti/Dominican Republic, China and Namibia. (2012)
  - RFA-HD-12-210: NIH/PEPFAR Collaboration for Advancing Implementation Science in Prevention of Maternal-Child HIV Transmission (PMTCT) (R01). Joint PEPFAR and NIH (NICHD-led; FIC, NIMH, ORWH participation) effort and funding, including FIC-led twice yearly meetings of RFA grantees and PMTCT implementers and policy-makers to enable a cross-fertilization of ideas, insights and experiences in PMTCT Implementation Science research. Funded 9 grants in Nigeria, Democratic Republic of Congo, South Africa, Zambia, Cote d'Ivoire, Kenya and Mozambique. (2012)
  - RFA-HD-14-027: Safety and Effectiveness of Triple Antiretroviral Drug Strategies for Prevention of Mother to Child HIV Transmission (R01). Funded 8 grants (one grant with additional funding from PEPFAR) in Kenya, South Africa, Malawi, Uganda, Zimbabwe and Botswana. (2014)
  - U.S.NIH - Brazil Biomedical Collaborative Research Initiative. Represented NICHD in this FIC/NIAID-led effort to stimulate research collaborations between NIH-funded investigators and Brazilian investigators. Initial opportunity: PA-14-328, Administrative Supplements for U.S. - Brazil Biomedical Collaborative Research. (2014)
- 2008-2015 International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) network (NIH/NICHD). DAIDS-led, NICHD-cofunded cooperative agreement for HIV prevention and treatment clinical trials in children and pregnant women.

- NICHD Representative for IMPAACT Leadership Committee (2013-2015)
- Complications Scientific Committee Member (2008- 2015)
- Medical Officer, 2-3 new protocols per year; 6-8 ongoing protocols per year.
- Protocol Principal (Co)Investigator:
- P1065: Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in HIV-Infected children and youth (2008-2013)
- P1076: Alendronate for HIV-infected children and youth with low bone density (2008-2015)
- P1084s: Maternal and infant monitoring for evidence of toxicity related to tenofovir use during pregnancy and breastfeeding (2009-2015)

2008-2015 Pediatric HIV/AIDS Cohort Study (PHACS) (NIH/NICHD). NICHD-led, multi-site domestic study (cooperative agreement), comprised of Surveillance Monitoring for Antiretroviral Treatment Toxicity (SMARTT) cohort study of infants born to women with HIV infection and Adolescent Master Protocol (AMP) cohort study of complications of perinatal HIV infection.

- Project Scientist (secondary)
- Scientific working group member (Cardiopulmonary, Hearing-Language, Complications and Leadership Group).
- Substudy Co-Principal Investigator, PH101: Newborn Evaluation for Effects of Maternal Tenofovir Use During Pregnancy

2008-2015 NICHD International Site Development Initiative (NISDI) perinatal and pediatric HIV multi-site cohort study in Latin America and the Caribbean. (Funded through Westat contract – see below) (NIH/NICHD).

- Investigator, Pediatric/PLACES cohort.
- (2011-2015) Principal Investigator, Perinatal /LILAC cohort
- Monitored study conduct. Co-led annual meetings. Led analyses and supported site investigator leadership of other analyses. Facilitated external investigator collaboration for projects using NISDI data/specimens, such as studies of vitamin D status in HIV-infected pregnant women, determinants of vertical hepatitis C transmission, and immunologic disturbances in HIV-exposed uninfected children.

2012-2015 Contract Officer's Representative (COR), NICHD Pediatric and Maternal HIV Clinical Trials Network (NIH/NICHD).

- Primary responsibility for running monitoring meetings with contractor (Westat), providing feedback and guidance on clinical research site performance and other activities for this large (>\$30M annually) contract.
- Responsible for technical aspects of developing RFP and making technical recommendations to Contract Officer after review of offeror proposals for recompetition of coordinating center contract (2012).
- Supervised development of Westat RFP to re compete NICHD/Westat clinical trials sites and supervise Westat conduct of site review meeting and process in 2014.

- Active promotion of participation of the NICHD clinical trials sites in studies of high priority that are developed by IMPAACT and other networks.

**2015-2018** Senior Pediatric Technical Advisor for PEPFAR, Office of the Global AIDS Coordinator (S/GAC), Department of State (2016-2019). Director, HIV Treatment, Care and TB unit. Long-term secondment (detail) from NIH to State Department (2015-2018).

- Primary pediatric accomplishments have included leadership, direction and technical oversight of the \$200 million, 2-year Accelerating Children on Treatment (ACT) Initiative and prevention, care and treatment activities for children/adolescents within PEPFAR country programs.

-(2016-2019) Pediatric and treatment representative for OGAC/PEPFAR in multi-stakeholder meetings, proposal development and document writing with WHO, UNICEF, Global Fund, Clinton Health Access Foundation, Elizabeth Glaser Pediatric AIDS Foundation, International AIDS Society, Gates Foundation, other USG agencies and other partners. [See Awards section: State Department Meritorious Honor Award, June 2018]

-(2017-2019) Major role in multi-stakeholder engagement, including with faith-based partners, in advancing progress in pediatric ARV drugs and diagnostics.

-(2016-2018) As Director of the HIV Treatment, Care and TB unit, act as direct supervisor for 3-5 senior staff members in adult treatment, TB/HIV, commodities and orphans-vulnerable children (OVC) activities.

-(2016-2018) S/GAC chair for the Kenya (>\$500M per year) and Lesotho PEPFAR country programs.

-(2017-2019) Co-lead of Epidemic Control Team 2, part of interagency strategic reorganization of PEPFAR headquarters technical support to country programs.

**2018-present** Medical Officer, Adult Clinical Branch, Office of HIV/AIDS (OHA), Division of Prevention, Care and Treatment, Global Health Bureau, USAID.

- Senior Pediatric Technical Advisor for PEPFAR, Office of the Global AIDS Coordinator (S/GAC), Department of State (2018-2019).

- Pediatric and treatment representative for PEPFAR in multi-stakeholder meetings, proposal development and document writing with WHO, UNICEF, Global Fund, Clinton Health Access Foundation, Elizabeth Glaser Pediatric AIDS Foundation, International AIDS Society, Gates Foundation, other USG agencies and other partners.

-(2018-2020) Senior Country Advisor (SCA) for the Kenya USAID PEPFAR country programs.

-(2018-2019) Co-lead of Epidemic Control Team 2, part of interagency strategic reorganization of PEPFAR headquarters technical support to country programs.

-(2019-present) OHA Deputy Principal. Focus countries: Lesotho (2018-2022), Kenya (2018-present), Cameroon (2019-present), Angola (2019-present), Haiti (2022-present).

- (2020-present) Senior Clinical & Technical Advisor for USAID COVID-19 response structures: Global Health COVID-19 Sustained Crisis Response Team (SCRT); Global Health COVID-19 Technical Working Group (TWG); USAID COVID-19 Response Team (CRT). Focus areas: Oxygen; Case management; Therapeutics; Test-to-Treat. OHA representative to SGAC-led PEPFAR COVID-19 ST3.



## **EDUCATIONAL ACTIVITIES**

### **Teaching:**

#### **Classroom Instruction**

- 1985-1988 Teaching Assistant, Neurosciences, Brown University
- 1988-1989 Teacher, Director & Principal. Louverture-Cleary School, Port-au-Prince, Haiti
- 1997-1998 Weekly pediatric resident lecture, Thomas Jefferson University
- 1998-1999 Pediatric Chief Resident, Johns Hopkins University  
Twice weekly “Chief Resident Rounds” for medical students  
Organize and facilitate weekly case conference  
Monthly “mock codes” for physician & nursing staff
- 2000-2003 Pediatric Infectious Diseases Fellow, Johns Hopkins University  
Pediatric Resident Noon Lectures: Medical complications of Influenza  
Pediatric Pulmonary Conference: Treatment of Influenza  
Pediatric Medical Student Conference: Respiratory Infections
- 2003-2008 Pediatric Resident Noon Lectures: MRSA (once yearly)  
Pediatric Medical Student Conference: Respiratory Infections (once yearly)
- 2006-2007 Course Lecturer, Second Year Medical Student Microbiology Course:  
Staphylococci (once yearly)
- 2006-2007 Doris Duke Fellowship Medical Students: Core pediatric HIV lectures (twice yearly)
- 2008-2010 Course lecturer, Rational Therapeutics course (Director: Brent Petty). Annual lecture about issues in medication prescribing in pediatrics.
- 2006-2013 Panelist, Ethiopian-Hopkins Telemedicine HIV Clinical Conference (once monthly)
- 2009-2011 Course lecturer, Tropical Medicine. West Virginia University Global Health Program, Lectures: Overview of HIV Epidemiology; Perinatal/Pediatric HIV Infection. (annual)
- 2012-2016 Course lecturer (Overview of research on antiretroviral treatment of HIV infection in children) for Pediatric HIV/AIDS (PubH 6099), Department of Epidemiology and Biostatistics, George Washington University School of Public Health. Course Director: R.J. Simonds, MD (2012-2014), Laura Guay (2015-2016). Washington, DC (once yearly).
- 2015 Course faculty and lecturer. American Academy of Pediatric Committee on Pediatric AIDS & St. Jude’s Children’s Research Hospital Pediatric HIV/AIDS Training Course, Feb. 17-18, 2015, Memphis, TN.
- 2016 Course lecturer. Mortality in Children Under 5 Years Old in Low- and Middle-Income Settings. For PUBH 396: Maternal & Child Health: A Global Imperative. Department of Health Studies, American University, Washington, DC.
- 2017 Course faculty and lecturer. American Academy of Pediatric Committee on Pediatric AIDS & St. Jude’s Children’s Research Hospital Pediatric HIV/AIDS Training Course, March 7-8, 2017, Memphis, TN.
- 2019 Course faculty and lecturer. American Academy of Pediatric Committee on Pediatric AIDS Pediatric HIV/AIDS Training Course, May 20-21, 2019, Chicago, IL.

- 2021 Course co-director, faculty and lecturer. American Academy of Pediatric Committee on Pediatric AIDS Pediatric HIV/AIDS Training Course, May 25-26, 2021, Chicago, IL (virtual).

### **Clinical Instruction**

- 1997-1998 Preceptor, Pediatric Resident Clinic, Thomas Jefferson University  
1997-1998 Preceptor, Pediatric Inpatient Service, Thomas Jefferson University  
2004-2005 Pediatric Resident Early Morning Report (once weekly)  
2003-2008 Preceptor, Pediatric Infectious Diseases Service  
2003-2019 Preceptor, Harriet Lane IPC (HIV) Clinic  
2019-present Preceptor, Yale-New Haven Hospital Pediatric Primary Care Center, 3-4 sessions per month.

### **CME Instruction & Invited Lectures**

- 2002 Anthrax, for Franklin Square Hospital Pediatric Grand Rounds  
2003 Tick-borne Illnesses, Johns Hopkins Pediatric Trends  
2003 Rational Use of Antibiotics, Johns Hopkins Pediatrics for the Practitioner  
2004 Prevention of Opportunistic Infections in HIV Infected Children, VI Brazil: JHU Conference on HIV/AIDS, Rio de Janeiro, **Brazil**  
2004 Immunization of HIV Infected Children, VI Brazil: JHU Conference on HIV/AIDS, Rio de Janeiro, **Brazil**  
2004 Staphylococcal Aureus Infections in Children, Baltimore, MD  
Pediatric Grand Rounds, St. Agnes Hospital  
Pediatric Grand Rounds, Greater Baltimore Medical Center  
Johns Hopkins Pediatric Trends  
2004 Pulmonary Complications of Pediatric HIV Infection. Johns Hopkins Pediatric Pulmonary Conference, Baltimore, MD.  
2004 Initiation of HIV Therapy in Newly Infected Youth, for Maryland Ryan White Title IV Initiative "Meeting the Needs of Youth Conference," Baltimore, MD.  
2004 MRSA (Methicillin Resistant Staphylococcus Aureus: Not Just for Hospitals Anymore. Pri-Med Mid-Atlantic Conference & Exhibition: Current Clinical Issues in Primary Care, Washington, DC, November 2004.  
2004 Otitis Media Update. Pri-Med Mid-Atlantic Conference & Exhibition: Current Clinical Issues in Primary Care, Washington, DC, November 2004  
2005 MRSA Infections in Children, Grand Rounds, Department of Dermatology, Johns Hopkins, March 2005.  
2005 Pediatric/Adolescent HIV Infection, Johns Hopkins 15<sup>th</sup> Annual Clinical Care of the Patient with HIV Infection, Baltimore, MD, April, 2005.  
2005 Antibiotic Treatment of Common Infections, Johns Hopkins Pediatrics for the Practitioner, Baltimore, MD.  
2005 Panelist. Interactive Session: Challenging Cases in Pediatric Infectious Diseases. Infectious Diseases Society of America, San Francisco, October 2005.  
2005 MRSA Infections in Children, Trends in Patient Management CME Conference for Maryland Academy of Physician Assistants, Maryland, October 2005.  
2006 Pediatric HIV diagnosis and management training seminar for physicians, nurses and pharmacists; weeklong course, Addis Ababa, **Ethiopia**, February, 2006.

- 2006 Pediatric Adolescent and HIV Infection, VII Brazil: JHU Conference on HIV/AIDS, Rio de Janeiro, **Brazil**, March, 2006.
- 2006 Pediatric Adolescent and HIV Infection, Johns Hopkins 16<sup>th</sup> Annual Clinical Care of the Patient with HIV Infection, Baltimore, MD, April, 2006.
- 2006 MRSA Infections in Children, Johns Hopkins Bayview Department of Pediatrics Grand Rounds, Baltimore, MD, April, 2006.
- 2006 MRSA Infections in Healthy Children: Impact on Athletes, Primary Care Approach to Treating Injured Athlete, Baltimore, MD, May 12, 2006.
- 2006 MRSA Infections in Children, Grand Rounds, Department of Pediatrics, SUNY Medical School, Stonybrook, New York, July 12, 2006.
- 2006 MRSA Infections in Children, Johns Hopkins Pediatrics for the Practitioner, Baltimore, MD, September 29, 2006.
- 2007 MTCTPlus: Family-centered approach to diagnosis and management of HIV infection. Principal instructor in week-long seminar for Healthcare professionals, Jacmel, **Haiti**, March 22-28, 2007.
- 2007 Meet the Professor: MRSA Infections, Society for Healthcare Epidemiology of America (SHEA) Annual Meeting, Baltimore, April 15 and 17, 2007.
- 2007 Mononucleosis in the Athlete, Primary Care Approach to Treating Injured Athlete, Baltimore, MD May 18, 2007.
- 2007 Pediatric Adolescent and HIV Infection, Johns Hopkins 17<sup>th</sup> Annual Clinical Care of the Patient with HIV Infection, Baltimore, MD, May 22, 2007.
- 2007 MRSA Infections: Not Just for Hospitals Anymore, Grand Rounds, Johns Hopkins Department of Dermatology, Baltimore, MD, June 6, 2007.
- 2007 MRSA Infections: Not Just for Hospitals Anymore, Grand Rounds, Anne Arundel Medical Center, Department of Pediatrics, Annapolis, MD, June 19, 2007.
- 2007 Co-Developer, Lecturer and Expert Panelist, Management of Pediatric HIV/AIDS in India, June-July 2007, Pune, India (on-line and videoconference) for Center for Clinical Global Health Education. Author and presenter for following lectures: Global Epidemiology of Pediatric HIV Infection; Prevention of Mother to Child Transmission of HIV; Diagnosing HIV in Infants and Children; Preventing Opportunistic Infections; Immunizations in HIV-Infected Children; Drug Interactions in Pediatric HIV Infection; Neuro- and Ophthalmologic Complications of HIV; Pulmonary Complications of HIV Hematologic Complications of HIV.
- 2007 Management of HIV-Infected Children in Low-Income Settings. Invited lecture for JHPIEGO, Johns Hopkins University, Baltimore, MD August 3, 2007.
- 2007 Evaluation of Fever in Young Infants, Pediatrics for the Practitioner, Johns Hopkins University, Baltimore, Maryland, September 28, 2007.
- 2007 Evaluation of Fever in Young Infants, Grand Rounds, Department of Pediatrics, St. Agnes Hospital, Baltimore, MD, October 26, 2007.
- 2008 Pediatric Adolescent and HIV Infection, VIII Brazil: JHU Conference on HIV/AIDS, Rio de Janeiro, **Brazil**, March, 2008.
- 2008 Pediatric Adolescent and HIV Infection, Johns Hopkins 18<sup>th</sup> Annual Clinical Care of the Patient with HIV Infection, Baltimore, MD, May 15, 2008.

- 2008 Management of Suspected Staphylococcal Infections in Children in the Era of Community MRSA. American Academy of Pediatrics-sponsored national webinar. May 15, 2008. Available at: [http://www.aap.org/saferhealthcare/webinar\\_12.html](http://www.aap.org/saferhealthcare/webinar_12.html)
- 2009 The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), Johns Hopkins Department of Pediatrics Grand Rounds. Joint presentation by Andrea Ruff, M.D., George Siberry, M.D., M.P.H., Nancy Hutton, M.D., Larry Wissow, M.D., M.P.H., and Harold Lehmann, M.D. Baltimore, MD January 28, 2009.
- 2009 Pediatric Adolescent and HIV Infection, Johns Hopkins 19<sup>th</sup> Annual Clinical Care of the Patient with HIV Infection, Baltimore, MD, May 5, 2009.
- 2009 Moderator, Session on Addressing Health Needs of Persons Living with HIV, Catholic Relief Services HIV Continuum of Care Conference, Washington, DC, Sept 15-16, 2009.
- 2009 Immunization of Perinatally HIV-Infected Infants and Children (*invited lecture*). Infectious Diseases Society of America Annual Meeting. Philadelphia, PA, November 1, 2009.
- 2010 Pediatric Adolescent and HIV Infection, IX Brazil: JHU Conference on HIV/AIDS, Rio de Janeiro, **Brazil**, April, 2010.
- 2010 The Impact of HIV Infection and Treatment on Bone Health in Children and Youth, Pediatric Grand Rounds, Tampa General Hospital, University of South Florida, Tampa, Florida, May 13, 2010.
- 2010 Immune reconstitution inflammatory syndrome (IRIS) in HIV-infected children. Florida/Caribbean AIDS Education and Training Center (AETC) 19<sup>th</sup> Annual HIV Conference, Orlando, Florida, May 14, 2010.
- 2010 Controversial Topics in Immunization of HIV-infected Children. 2nd International Workshop on HIV Pediatrics, 16-17 July 2010, Vienna, **Austria**.
- 2010 The Bare Bones of HIV, Vitamin D, Tenofovir and Bone Mineral Density. Lunch-n-Learn Webinar for St Jude Research Hospital (Memphis) and University of South Florida (Tampa). 7 September 2010.
- 2010 Immunizations in Pediatric HIV Infection. World AIDS Day Grand Rounds, Children's National Medical Center, Washington, DC. 1 December 2010.
- 2011 Evaluation of HIV-Related Bone Mineralization Problems in Infants and Children. International Society for Clinical Densitometry (ISCD) Annual Meeting, Miami, Florida. 7 April 2011.
- 2011 Pediatric HIV Update: Implications for Pediatric HIV Care and Treatment. PEPFAR Annual Meeting, Johannesburg, **South Africa**. 4 May 2011.
- 2011 Bone health in HIV-infected children. Florida/Caribbean AIDS Education and Training Center (AETC) 20<sup>th</sup> Annual HIV Conference, Orlando, Florida. 13 May 2011.
- 2011 Dyslipidemia and Insulin Resistance in Pediatric HIV Infection: Implications for Cardiovascular Health. Florida/Caribbean AIDS Education and Training Center (AETC) 20<sup>th</sup> Annual HIV Conference, Orlando, Florida. 13 May 2011.
- 2011 Update on Prevention of Maternal-to-Child HIV Transmission. 10th National Meeting on Pediatric AIDS, São Paulo, **Brazil**. 17 November 2011.
- 2011 Pediatric HIV Morbidity and Mortality in the HAART Era. 10th National Meeting on Pediatric AIDS, São Paulo, **Brazil**. 17 November 2011.
- 2012 Session moderator at 19<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI), "Recognizing Risk in HIV-Exposed and Infected Infants." Seattle, March 5-8, 2012.

- 2012 Aging Perinatally Infected Youth: Co-morbidities and Implications. Conference: The Graying of HIV: An Aging and Growing Population, Johns Hopkins AIDS Education and Training Center (AETC), Baltimore, MD, March 20, 2012.
- 2012 Management of children with HIV infection: Progress and gaps. Presentation for JHPIEGO, Washington, DC, Dec. 19, 2012.
- 2013 Pediatric HIV Infection: Past Successes, Current Challenges, Future Directions. Johns Hopkins School of Medicine, Department of Pediatrics Grand Rounds, Baltimore, MD, April 3, 2013.
- 2013 Vitamin D and Adolescents with HIV Infection, Florida/Caribbean AIDS Education and Training Center (AETC), Webinar, Nov. 14, 2013.
- 2013 Vitamin D and Adolescents with HIV Infection, HIV Lunch-n-Learn Series, St. Jude Children's Research Hospital, Webinar, Dec. 3, 2013.
- 2014 Presentation and Meet the Professor session on progress and remaining barriers in PMTCT. II International Conference – CICAL (Coordinacion de Investigacion Clinica Academica en Latinoamerica) 2014 “Present and Future of Science Applied to Infectious Diseases” Buenos Aires, **Argentina**, July 2-3, 2014
- 2014 Invited plenary presentation: Persistent Inflammation despite effective ART in Children with controlled HIV-infection. 6th International Workshop on HIV Pediatrics, 18-19 July 2014, Melbourne, **Australia**.
- 2014 Invited to deliver the Grand Rounds Barrett Lecture for UT-Southwestern Medical Center. Pediatric HIV Infection: Past Successes, Current Challenges, Future Directions. October 22, 2014, Dallas, Texas.
- 2016 High Rates of HIVDR Complicate ART Choices for Children and Adolescents, for Consultation on Global Trends of HIV Drug Resistance, National Institute of Allergy of Infectious Diseases, May 3-4, 2015, Bethesda, Maryland.
- 2016 Keynote speaker for Ugandan 8th National Pediatric & Adolescent HIV Conference. 90-90-90 for Children: Progress & Barriers. October 5, 2016. Kampala, **Uganda**.
- 2017 Invited speaker : Overview of timing and methods for infant HIV testing. WHO-convened Regional workshop on innovating and strengthening the Post-Natal package of HIV services in the African Region. June 20-23, 2017, Johannesburg, **South Africa**.
- 2017 Invited plenary presentation: What We Have Learned from the ACT Initiative – Identifying and Treating Children with HIV Infection. 9th International Workshop on HIV Pediatrics, 20-21 July 2017, Paris, **France**.
- 2017 Invited speaker: Providing Antiretroviral Drugs to People Living with HIV in PEPFAR-supported programs. American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, 14 November 2017, San Diego, California.
- 2017 Invited speaker: What Have We Learned from the ACT Initiative – Identifying and Treating Children with HIV Infection. WHO/EGPAF Conference: Accelerating efforts to scale up timely diagnosis and treatment for children and adolescents living with HIV. 3 December 2017, Abidjan, **Cote d'Ivoire**.
- 2017 Invited speaker: Reaching Men - Using data to focus programs on specific locations and populations for maximal impact. UNAIDS/Sonke Gender Justice Organization session: ‘Innovative partnerships to drive male engagement for the ending of AIDS’, 5 December 2017, 19th International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA 2017), Abidjan, **Cote d'Ivoire**.

- 2019 Invited speaker: PEPFAR – Where we’ve been and where we’re headed. Center for Interdisciplinary Research on AIDS (CIRA), Yale University, 2019 February 5, New Haven, Connecticut.
- 2021 Invited Panelist: COVID & Adolescent HIV: What now? NIH Joint AHISA, PATC3H, AGYM Forum Meeting. 2021 February 16, Bethesda, MD (Virtual).
- 2022 Invited Speaker: 4th Annual Lawrence R. Stanberry, MD, PhD Lectureship in Global Health, Columbia University Department of Pediatrics Grand Rounds (virtual). “Progress and Remaining Challenges in Eliminating HIV Infection in Children - Lessons for a Pediatrician in Global Health” 28 January 2022, New York, New York.
- 2022 Co-organizer, Co-Moderator & Speaker: American Academy of Pediatrics (AAP) Section on Global Health (SOGH) and Committee on Pediatric and Adolescent HIV (COPAH) joint webinar, “Global Pediatric HIV Update”. November 17, 2022. Recording available at:  
<https://aap.webex.com/recordingservice/sites/aap/recording/7acfb36a48ae103ba1ce729df506a9a9/playback>

## **Mentoring**

- 2005-2010 Aaron E. Chen, MD. Present Position (2014): Assistant Professor of Clinical Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania School of Medicine. Mentored during Emergency Medicine fellowship and while junior faculty member in MRSA clinical epidemiology project that resulted in publication (Chen AE, Goldstein M, Carroll K, Song X, Perl TM, Siberry GK. *Pediatr Emerg Care*. 2006;22(10):717-723) and that formed basis for successful funding by Thrasher Foundation (PI: Chen; Mentor: Siberry. 7/01/06-6/30/08) for randomized trial. Trial successfully completed with primary outcomes reported in major journal (Chen AE, Carroll KC, Diener-West M, Ross T, Ordun J, Goldstein MA, Kulkarni G, Cantej JB, Siberry GK. *Pediatrics* 2011;127(3):e573-80).
- 2005-2006 Renata Arrington-Sanders, MD. Present Position (2014): Assistant Professor, Department of Pediatrics, Johns Hopkins University School of Medicine. Mentored as adolescent medicine fellow in clinical project assessing clinical consequences of drug interaction between antiretroviral ritonavir and inhaled corticosteroids, resulting in peer-reviewed publication (Arrington-Sanders R, Hutton N, Siberry GK. *Pediatr Infect Dis J* 2006;25(11):1044-48. ).
- 2005-2006 Kari Gillenwater, MD. Present Position (2014): Clinical Associate Professor, Department of Pediatrics, University of Washington. Mentored during residency in project to evaluate PPD conversion trends in children's rehabilitation hospital, resulting in peer-reviewed publication (Gillenwater KA, Sapp SC, Pearce K, Siberry GK. *Am J Infect Control* 2006;34(10):651-4.).
- 2006-2007 Jillian Szczesiul, PharmD. Present Position (2014): Clinical Specialist, Emergency Medicine, Mt. Sinai Hospital (Chicago). Mentored during pharmacy residency in clinical epidemiology project to evaluate trends in clindamycin susceptibility in pediatric community-associated MRSA infections, resulting in peer-reviewed publication (Szczesiul JM, Shermock KM, Murtaza UI, Siberry GK. *Pediatr Infect Dis J* 2007; 26(9):852-4.).
- 2018-2019 Steven Towers, Candidate, Masters of Public Health Degree, Department of Epidemiology and Biostatistics, The George Washington University School of Public Health and Health Services, Washington, DC. Site preceptor for development of Masters thesis.
- 2020-present Mentor for International AIDS Society (IAS) Abstract Mentor Program (AMP). Program objective is to help young or less experienced researchers improve their abstracts before submitting them, to increase the chance of their work being accepted for presentation at International AIDS or IAS conferences.

## **CLINICAL ACTIVITIES**

### **Certification & Licensure:**

1995	Diplomate, National Board of Medical examiners
1997	Diplomate, General Pediatrics, American Board of Pediatrics (1997-2004)
1997	Pennsylvania Medical License – MD061593-L [expired]
1997	Delaware Medical License – C1 0005057 [expired]
2001-present	Maryland Medical License – D0058090
2003	Diplomate, Pediatric Infectious Diseases, American Board of Pediatrics(2003-2010)
2004-present	Maintenance of Board Certification, General Pediatrics
2010-present	Maintenance of Board Certification, Pediatric Infectious Diseases
2018-present	Connecticut Medical License – 61686
2021-present	New York Medical License - 313096

### **Clinical Program Leadership**

2003-2008 Medical Director, Harriet Lane Clinic. Led successful re-design of and relocation into new clinical building of the principal ambulatory pediatric training site at Johns Hopkins (2005-2006), including reorganization of patient care process; development and adoption of new technologies for patient tracking, ordering and documentation; and institutionally recognized leadership of multidisciplinary, interdepartmental team to reach successful outcome. Additional accomplishments included:

- Establishment of HLC Research Review Committee process to review, monitor, and assist with all clinical research activities taking place in HLC
- Establishment of HLC Resident Advisory Committee (RAC), a monthly meeting of housestaff, preceptors, and nursing which developed proposals for improving clinic processes, planning initiatives, and enhancing patient care and resident educational experiences in HLC
- Establishment of HLC website to facilitate access of providers and staff to clinic policies and procedures, important forms, and educational and patient-care resources
- Establishment of HLC Community Advisory Board (CAB) under leadership of senior social worker Carrie Vick. Quarterly meetings of HLC parents and caretakers and adolescent patients, drawn from all care groups (HLPC, Adolescent Medicine, IPC), to provide input about HLC quality of care, initiatives and services.
- Launching of “Quality Dashboard” initiative to provider real-time and multi-level feedback about immunization rates in HLC, together with Center for Innovation.
- Establishment (together with HLC Nursing) of HLC as a CDC sentinel surveillance site for monitoring influenza (one of only 2 sites in the State of Maryland)
- Receipt of annual Baltimore City Health Department Awards for Excellence in Immunization Practice: 2004, 2005, 2006, 2007, 2008



- Establishment of expanded on-site services in HLC, including dentistry, Infant & Toddlers developmental evaluations, WIC

### **Clinical Service Responsibilities:**

2003-2006	Harriet Lane Clinic, half-day session per week
2003-2008	Intensive Primary Care (Pediatric/Adolescent HIV) Clinic, 2 sessions per week
2003-2008	Pediatric Infectious Diseases, Consultation Service, 4 weeks per year
2008-2018	Intensive Primary Care (Pediatric/Adolescent HIV) Clinic, 1 session per week
2019-present	Preceptor, Yale Pediatrics – Yale New Haven Hospital Primary Care Center, 3-4 sessions per month.

## **ORGANIZATIONAL ACTIVITIES**

### **Institutional Committees and Appointments:**

2003-2008	Director, Harriet Lane Clinic (JHU)
2003-2008	Pediatric Clinical Practice Association- Pediatric Finance Committee(JHU)
2004-2006	Pediatric Clinical Practice Association (elected 2004) (JHU)
2006-2008	Member, Pharmacy & Therapeutics Committee, Johns Hopkins Healthcare
2006-2007	Steering Committee Member, Microbiology Laboratory Information System
2006-2008	Representative, Johns Hopkins Medical School Council [Elected 2006]
2009-2015	Member, Office of AIDS Research (OAR) Working Group-Training, Infrastructure and Capacity Building (NIH)
2010-2015	Member, Federal Working Group on Bone Diseases(NIH)
2011-2015	NICHD representative, Trans-NIH Committee on Viral Hepatitis (appointed by NICHD Director) (NIH)
2012-2015	Member, DAIDS Grading Table Working Group (NIH)
2013-2015	NICHD representative, NIH Director's Office Liaison to the US Preventive Services Task Force (USPSTF) (appointed by NICHD Director) (NIH)
2013-2015	NICHD representative, NIH DSMB Working Group (convened by NIH Office of the Director) (NIH)
2014-2015	Member, Office of AIDS Research (OAR) Working Group-Research in International Settings(NIH)
2013-2016	Member, Pediatric Adverse Events Terminology Working Group (led by NICHD). Co-chair, Pediatric Infectious Disease Working group.
2014-2017	NICHD liaison to American Academy of Pediatrics (AAP) Committee on Pediatric AIDS (COPA).

### **Scientific Reviewer for Research Proposals**

2010	Reviewer, Wellcome Trust. Review of applications in 2010, 2014.
2011	Reviewer, Fogarty International Center (FIC), Global Health Initiative / Women's Health Supplements.
2011-2014	Reviewer, South Africa Medical Research Council. Review about one research application per year.

- 2012-2014 Reviewer, Office of AIDS Research (OAR), NIH. Intramural-to-China applications (2012). Intramural-to-India applications (2013).
- 2013 Reviewer, Netherlands Organisation for Scientific Research, Innovative Research Incentives Scheme – Veni Grants.
- 2018-present Reviewer, International AIDS Society, (IAS) Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) annual grant proposals.

**Professional Societies (active):**

- 1998-present Fellow, American Academy of Pediatrics (AAP)  
 -NICHHD liaison to Committee on Pediatric AIDS (COPA) (2014-2018)  
 -Section on International Child Health (SOICH) member of Committee on Pediatric AIDS (COPA) (2018-present)
- 2000-present Member, Infectious Disease Society of America (IDSA). HIV Medical Association (HIVMA)
- 2000-present Member, Pediatric Infectious Disease Society (PIDS)  
 Advanced to Fellow in 2014  
 -PIDS Communications Committee Member (May 2010-2015)  
 -Chair, PIDS Communications Committee (December 2010-2014). Duties include oversight and management of all blast emails to PIDS members and the PIDS website; writing/editing articles for monthly PIDS newsletter; twice yearly written reports to the PIDS Council.
- 2020-present Member, European Society for Pediatric Infectious Disease (ESPID).

**Editorial Activities:**

**Editorial Board Appointments**

- 2002-2013 Section Editor, Pediatric Puzzler, *Contemporary Pediatrics*. Review submissions and work with contributors to produce monthly didactic teaching case.
- 2011-present Associate Chief Editor (HIV/AIDS), *Pediatric Infectious Disease Journal*

**Journal Peer Review Activities (initial year)**

- 2003 Manuscript reviewer, *Pediatric Infectious Diseases Journal*
- 2004 Manuscript reviewer, *Pediatric Blood and Cancer*
- 2004 Manuscript reviewer, *Clinical Microbiology and Infection*
- 2004 Manuscript reviewer, *Clinical Infectious Diseases*. (awarded outstanding reviewer designation by editors – February 2008; April 2010)
- 2005 Manuscript reviewer, *AIDS Research and Human Retroviruses*
- 2005 Manuscript reviewer, *Journal of Perinatology*
- 2005 Manuscript reviewer, *Journal of Pediatrics*
- 2006 Manuscript reviewer, *AIDS Patient Care and STDs*
- 2006 Manuscript reviewer, *American Journal of Infection Control*
- 2009 Manuscript reviewer, *Expert Opinion on Drug Safety*
- 2009 Manuscript reviewer, *Bulletin of the World Health Organization*
- 2010 Manuscript reviewer, *Lancet Infectious Diseases*
- 2010 Manuscript reviewer, *Journal of the Acquired Immunodeficiency Syndrome*
- 2010 Manuscript reviewer, *Vaccine*
- 2011 Manuscript reviewer, *Journal of Pediatric Gastroenterology and Nutrition*

- 2011 Manuscript reviewer, *International Journal of STDs and AIDS*
- 2012 Manuscript reviewer, *Journal of the Pediatric Infectious Disease Society*
- 2012 Manuscript reviewer, *AIDS*
- 2012 Manuscript reviewer, *HIV Medicine*
- 2012 Manuscript reviewer, *Journal of Allergy and Clinical Immunology*
- 2015 Manuscript reviewer, *Journal of the International AIDS Society*

**Other**

- 2003- 2009 Faculty Member, Johns Hopkins AIDS Service Expert Q&A  
<http://www.hopkins-aids.edu/ask.html> Interactive, Q & A services designed to provide clinicians and patients the opportunity to draw on the expertise of HIV specialists at The Johns Hopkins AIDS Service by posting questions that will be answered on line.
- 2004 Question writer for certifying exam of Pediatric Infectious Diseases
- 2008-2010 Peer Reviewer, UpToDate (Pediatrics), UpToDate, Inc, Waltham, MA. Topics: Methicillin-resistant *S. aureus*. Fever.
- 2010-present Abstract reviewer, International AIDS Society.
- 2011-present Abstract reviewer, International Workshop on HIV Pediatrics.
- 2018 Reviewer, Screening for HIV Infection in Pregnant Women: A Systematic Review for the U.S. Preventive Services Task Force (USPSTF).

**Advisory & Scientific Committees:**

- 2007-2010 Member, DHHS Working Group: Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children.
- 2007-present Member, DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.
- 2009 Participant and Rapporteur in Expert Consultation on Operational Research on PMTCT and paediatric HIV Care, Support and Treatment, organized by UNICEF, WHO and UNAIDS, in collaboration with the Elizabeth Glaser Pediatric AIDS Foundation and George Washington University, Washington, DC, Sept 9-11, 2009.
- 2009-2015 Member, Pediatric-PMTCT Technical Working Group, PEPFAR. NIH representative and speaker/moderator at PEPFAR Implementer Meetings: 2009 (Windhoek, Namibia); 2010 (Arusha, Tanzania); 2011 (Johannesburg, South Africa); 2014 (Durban, South Africa), Member, HHS Day organizing committee.
- 2010 HIV/AIDS Bureau, Pediatric Quality Measures Workgroup, Washington, DC, Jan 11-12, 2010.
- 2010-2018 Member (2010-2018), **Executive Secretary (2010-2018)**, DHHS Working Group: Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children.
- 2012-present Member, World Health Organization (WHO) Maternal Child Health Guideline Development Group for Antiretroviral Treatment.
- 2013-present Member (2013-present), **Executive Secretary (2014-2017)**: DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal

- Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States.
- 2013-present Member, Pediatric Antiretroviral Working Group (PAWG), WHO.
- 2013 CoChair, WHO expert panel to review role of CD4 monitoring in HIV care programs. Geneva, Switzerland, Sept. 16-17, 2013.
- 2013 CoChair, WHO expert panel to review infant HIV diagnosis in HIV care programs. Geneva, Switzerland, Sept. 18-19, 2013.
- 2014 Member, WHO Consultation on Chronic Comorbidities in People Living with HIV Infection. Geneva, Switzerland, July 8-9, 2014.
- 2014-present Member, Scientific Committee, International Workshop on HIV Pediatrics. Annual meetings.
- 2016-present Member, WHO Pediatric Antiretroviral Drug Optimization (PADO) group.
- 2017 Panelist and Moderator, FDA Workshop: Developing Rabies Monoclonal Antibody Products as a Component of Rabies Post-Exposure Prophylaxis. White Oak, Maryland. July 17, 2017.
- 2018-present Scientific Advisory Board Member, African Cohort Study (AFRICOS), US Military HIV Research Program, Bethesda, Maryland.
- 2019-present Member, Advisory Antimicrobial Drugs Advisory Committee, U.S. Food and Drug Administration (FDA), White Oak, Maryland.

## **RECOGNITION**

### **Honors & Awards:**

- 1988 Award for Excellence in Teaching in Neuroscience, Brown University
- 1988 Phi Beta Kappa, Brown University
- 1988 Sigma Xi Science Honor Society, Brown University
- 1991 Pediatric AIDS Foundation Summer Internship
- 1994 Alpha Omega Alpha Medical Honor Society, Johns Hopkins School of Medicine
- 1994 Harrison Award in Pediatrics, Johns Hopkins School of Medicine
- 1994 Delta Omega Public Health Honor Society, Johns Hopkins School of Hygiene
- 1997 Kamsler Resident Award in Pediatrics, Department of Pediatrics, Johns Hopkins Hospital
- 2000 Family Practice Residency Teaching Award, Bryn Mawr Hosp., Bryn Mawr, PA
- 2001 Harriet Lane House Staff Fellow Appreciation Award
- 2003 Travel Grant for Excellence in abstract submission, IDSA, October 2003
- 2005 General Pediatrics Division Resident Teaching Award
- 2008 Baltimore Mayor Sheila Dixon proclamation of June 11, 2008 as “Dr. George Kelly Siberry Day” in Baltimore City, in recognition of “achievements and contributions of Dr. Siberry”
- 2010 NIH Director’s Award, July 15, 2010, Bethesda, MD. “For leading [with co-recipients] a comprehensive and coordinated response to the H1N1 influenza pandemic.”
- 2010 NIH Merit Award, NICHD Director’s Award Ceremony, December 8, 2010, Bethesda, MD. “In recognition of leadership in the evaluation of the effects of intrauterine antiretroviral drug exposure on infants and children”

- 2011 NICHD Collaboration Award (2011) with Rohan Hazra and Yasaman Shirazi, NICHD Director’s Award Ceremony, January 18, 2012. “For leadership in the development of successful multi-institute partnerships in the PHACS Study that have led to exceptional multi-disciplinary research and scientific excellence.”
- 2017 NIAID Merit Award, February, 2017, Bethesda, MD. “For outstanding leadership and teamwork [with co-recipients]in advancing NIH's collaboration with PEPFAR on implementation science projects to reverse the AIDS epidemic.”
- 2018 State Department Meritorious Honor Award, June 2018, Washington, DC: “In recognition of Dr. George Siberry’s outstanding technical contributions to the field of global pediatric HIV/AIDS. He has translated his superior knowledge to practice in representing the Department of State and Office of the Global AIDS Coordinator as a global thought leader with UNAIDS, WHO and other key global partners in the development and implementation of critical policies and guidelines for children infected and affected by HIV/AIDS”

**FOREIGN LANGUAGES**

Haitian Creole	Written and spoken, moderate proficiency
Spanish	Written and spoken, moderate proficiency
French	Written and spoken, limited proficiency
Portuguese	Written, limited proficiency